NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 1 of 88
Coordi
nating Centre 
University of Calgary  
Foothills Medical Center  
1403 29th Street NW 
Calgary, AB T2N 2T9 
Sponsor  
No
NO Inc.  
Krembil Research Institute 
8KD-406, 60 Leonard Avenue 
Toronto, ON Canada M5T 2S8 
A Mult
icentre, Randomized, Double- blinded, Placebo -controlled, Parallel Group, Single-
dose Design to Determine the Efficacy and Safety of Intravenous NA- 1 in Subjects with 
Acute Ischemic Stroke Undergoing Endovascular Thrombectomy (ESCAPE -NA1  Trial)  
PROTOCOL NA-1-007 , Version  9.0  
(AMENDMENT # 8) 
ISSUE DATE: 19th February  2019 
Health Authority File Number:  EudraCT number 2016 -001826 -33 
clinicaltrials.gov number [STUDY_ID_REMOVED]  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 3 of 88
Table of Contents 
1 GENERAL INFORMATION ................................................................................................ 2 
1.1 SIGNATURES OF APPROVAL  ............................................................................................................... 2 
1.2 LIST OF ABBREVIATIONS .................................................................................................................... 8 
2 STUDY SYNOPSIS  ............................................................................................................... 11 
3 COORDINATING CENTRE,  SPONSOR, INVESTIGATORS AND FACILITIES  ..... 18 
4 BACKGROUND INFORMATI ON ..................................................................................... 20 
4.1 RATIONALE  ....................................................................................................................................... 20 
4.2 THE NEUROPROTECTANT , NA-1 ..................................................................................................... 20 
4.3 SUMMARY FROM NONCLINICAL STUDIES AND CLINICAL TRIALS  ................................................ 21 
4.3.1  NONCLINICAL STUDIES  22 
4.3.2  CLINICAL TRIALS  25 
4.4 SUMMARY OF KNOWN POTENTIAL RISKS AND BENEFITS  ............................................................. 27 
4.4.1  PHASE 1 STUDY  27 
4.4.2  PHASE 2 STUDY (ENACT)  27 
4.4.3  SUMMARY OF SAFETY OF NA-1  28 
4.5 DESCRIPTION OF AND JUSTIFICATION FOR THE  ROUTE OF ADMINISTRATION , DOSAGE , DOSAGE 
REGIMEN AND TREATMENT PERIOD  ........................................................................................................ 28 
4.6 TARGET PATIENT SELECTION  ......................................................................................................... 28 
4.7 ENDOVASCULAR ACUTE STROKE THERAPY  ................................................................................... 29 
4.8 IMAGING AS A BIOMARKER FOR PATIENT SELECTION  .................................................................. 30 
5 TRIAL OBJECTIVES  .......................................................................................................... 32 
5.1 PRIMARY OBJECTIVE  ....................................................................................................................... 32 
5.2 SECONDARY OBJECTIVES  ................................................................................................................ 32 
5.3 TERTIARY OBJECTIVES  .................................................................................................................... 32 
5.4 LEADING SAFETY OBJECTIVES  ........................................................................................................ 32 
6 TRIAL DESIGN .................................................................................................................... 33 
6.1 OUTCOMES  ........................................................................................................................................ 33 
6.1.1  PRIMARY EFFICACY OUTCOME  33 
6.1.2  SECONDARY EFFICACY OUTCOMES  33 
6.1.3  TERTIARY OUTCOMES  33 
6.1.4  SAFETY OUTCOMES OF SPECIAL INTEREST  34 
6.2 RANDOMIZATION AND BLINDING  .................................................................................................... 35 
6.3 PROCEDURE FOR BREAKING THE RANDOMIZATION CODE ........................................................... 36 
6.4 TREATMENT  ...................................................................................................................................... 37 
6.4.1  DOSAGE FORM, ACCOUNTABILITY AND LABELING  37 
6.4.2  DISPOSITION OF STUDY DRUG SUPPLIES  37 
6.5 STUDY DRUG MONITORING  ............................................................................................................. 38 
6.6 CASE REPORT FORMS  ...................................................................................................................... 38 
6.7 PROCESS , TIMING AND QUALITY ASSURANCE METRICS  ............................................................... 38 
7 SELECTION AND WITHDRAWAL OF SUBJECTS  ..................................................... 39 
7.1 STUDY ENROLMENT PROCESS  ......................................................................................................... 39 
7.2 INCLUSION CRITERIA  ....................................................................................................................... 39 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 4 of 88
7.3 EXCLUSION CRITERIA  ...................................................................................................................... 40 
8 TREATMENT OF SUBJECTS  ........................................................................................... 42 
8.1 STUDY INTERVENTIONS  .................................................................................................................... 42 
8.1.1  ADMINISTRATION OF STUDY DRUG 42 
8.2 INTERVENTIONS  ................................................................................................................................ 43 
8.2.1  ENDOVASCULAR INTERVENTION  43 
8.3 GUIDELINES -BASED MEDICAL /STROKE UNIT CARE ...................................................................... 43 
8.4 SPEED OF INTERVENTION  ................................................................................................................. 45 
8.5 CONSENT PROCESS  ........................................................................................................................... 45 
8.6 BASELINE CLINICAL AND LABORATORY EVALUATIONS  ............................................................... 46 
8.7 IMMUNOGENICITY SUBSTUDY  ......................................................................................................... 46 
8.7.1  IMMUNOGENICITY SAMPLE COLLECTION  46 
8.7.2  IMMUNOGENICITY SAMPLE STORAGE AND SHIPMENT  47 
8.8 PHARMACOKINETICS SUBSTUDY  ..................................................................................................... 47 
8.8.1  PK SAMPLE COLLECTION  47 
8.8.2  PK SAMPLE STORAGE AND SHIPMENT  47 
8.9 BRAIN AND NEUROVASCULAR IMAGING  ......................................................................................... 48 
8.10  STUDY DRUG ADMINISTRAT ION .................................................................................................... 48 
8.11  EVALUATIONS FOLLOWING RANDOMIZATION  ............................................................................ 48 
8.12  IMAGING  .......................................................................................................................................... 49 
8.13  CRITERIA FOR DISCONTINUATION FROM THE STUDY  ................................................................. 49 
9 ASSESSMENT OF EFFICA CY .......................................................................................... 50 
9.1 THE MODIFIED RANKIN SCALE  ....................................................................................................... 50 
9.2 THE NATIONAL INSTITUTES OF HEALTH STROKE SCALE  ............................................................. 50 
9.3 BARTHEL INDEX  ............................................................................................................................... 50 
9.4 MORTALITY RATE ............................................................................................................................ 50 
9.5 EQ-5D-5L .......................................................................................................................................... 50 
9.6 VOLUME OF STROKES  ...................................................................................................................... 51 
9.7 COGNITIVE OUTCOMES .................................................................................................................... 51 
9.8 PHARMACOKINETICS ASSESSMENT  ................................................................................................. 51 
9.9 ADDITIONAL ASSESSMENTS  ............................................................................................................. 51 
10 ASSESSMENT OF SAFETY  ............................................................................................. 53 
10.1  ADVERSE EVENT DEFINITIONS  ...................................................................................................... 53 
10.2  CLINICAL MANAGEMENT OF ADVERSE EVENTS  .......................................................................... 55 
10.2.1  EARLY STUDY DRUG CESSATION  55 
10.2.2  TREATMENT OF HYPOTENSION  55 
10.2.3  INCREASES IN HISTAMINE  56 
10.2.4  HYPERGLYCEMIA  56 
10.3  IDENTIFICATION OF ADVERSE EVENTS BY THE INVESTIGATOR  ................................................. 56 
10.4  REPORTING OF ADVERSE EVENTS  ................................................................................................. 57 
10.5  REPORTING OF SERIOUS ADVERSE EVENTS  ................................................................................. 57 
10.5.1  REPORTING BY THE INVESTIGATOR  57 
10.5.2  REPORTING SAE S TO THE HEALTH AUTHORITIES AND ETHICS COMMITTEES  58 
10.6  ADDITIONAL SAFETY ASSESSMENTS  ............................................................................................. 58 
10.6.1  VITAL SIGNS  58 
10.6.2  BIOCHEMISTRY AND HEMATOLOGY  59 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 5 of 88
10.7  12-L EAD ELECTROCARDIOGRAM MONITORING . ......................................................................... 59
10.8  CONCOMITANT MEDICATIONS  ...................................................................................................... 59 
10.9  SAFETY AND DATA REVIEW  ........................................................................................................... 59 
10.10  FOLLOW -UP AND REPORTING OF PREGNANCIES  ....................................................................... 59 
11 STATISTICS  ....................................................................................................................... 61 
11.1  SAMPLE SIZE CONSIDERATIONS  .................................................................................................... 61 
11.2  ANALYSIS POPULATIONS  ................................................................................................................ 61 
11.2.1  ITT  POPULATION  61 
11.2.2  PER PROTOCOL POPULATION  61 
11.3  ANALYSIS OF PRIMARY EFFICACY OUTCOME  ............................................................................. 61 
11.4  KEY SECONDARY OUTCOME ANALYSIS  ........................................................................................ 62 
11.5  ANALYSIS OF SECONDARY EFFICACY OUTCOMES  ....................................................................... 63 
11.5.1  MODIFIED RANKIN SCALE – SHIFT ANALYSIS  64 
11.5.2  NATIONAL INSTITUTES OF HEALTH STROKE SCALE  64 
11.5.3  BARTHEL INDEX  64 
11.5.4  MORTALITY RATE 64 
11.5.5  MODIFIED RANKIN SCALE – 0-1 DICHOTOMY ANALYSIS  64 
11.6  ANALYSIS OF TERTIARY EFFICACY OUTCOMES  .......................................................................... 64 
11.6.1  EQ-5D-5L  64 
11.6.2  VOLUME OF STROKE  64 
11.6.3  COGNITIVE OUTCOMES  64 
11.6.4  MRS AT 30 DAYS 65 
11.6.5  PHARMACOKINETICS  65 
11.7  ADJUSTMENT FOR COVARIATES AND SUBGROUP ANALYSES  ...................................................... 65 
11.8  HANDLING OF MISSING , UNUSED AND SPURIOUS DATA .............................................................. 65 
11.9  ANALYSES OF SAFETY  .................................................................................................................... 65 
11.9.1  SAE S 65 
11.9.2  MORTALITY  66 
11.9.3  AES 66 
11.9.4  VITAL SIGNS  66 
11.9.5  LABORATORY AND 12-L EAD ECG  RESULTS  66 
11.9.6  PRIOR AND CONCOMITANT MEDICATIONS  66 
11.10  INDEPENDENT DATA MONITORING COMMITTEE ....................................................................... 66 
12 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  ............................................... 68 
13 QUALITY CONTROL AND QUALITY ASSURANCE  ................................................ 69 
13.1  AUDITS AND INSPECTIONS  .............................................................................................................. 70 
13.2  PROTOCOL AMENDMENTS AND REVISIONS  .................................................................................. 70 
14 ETHICS  ................................................................................................................................ 71 
14.1  RESEARCH ETHICS BOARD /INSTITUTIONAL REVIEW BOARD  .................................................... 71 
15 DATA HANDLING AND RECORDKEEPING  .............................................................. 72 
15.1  DATA HANDLING  ............................................................................................................................ 72 
15.2  INVESTIGATOR FILES/RETENTION OF DOCUMENTS  .................................................................... 72 
15.3  SOURCE DOCUMENTS AND BACKGROUND DATA ......................................................................... 72 
15.4  CASE REPORT FORMS  .................................................................................................................... 73 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 6 of 88
15.5  CONFIDENTIALITY  .......................................................................................................................... 73 
16 PUBLICATION AND PRESENTATION POLICY ........................................................ 74 
17 ANCILLARY STUDIES POLICY  .................................................................................... 74 
18 DATA- SHARING PLAN .................................................................................................... 75 
19 FINANCIAL CONSIDERATIONS  ................................................................................... 76 
20 APPENDIX 1 – ADDITIONAL GUIDANCE ON IMAGING SELECTION AND 
ENDOVASCULAR TREATMENT  .......................................................................................... 77 
21 APPENDIX 2: DERIVATION OF ASPECTS ON NCCT AND COLLATERALS 
SCORING ON CTA  ................................................................................................................... 81 
22 APPENDIX 3 – RANDOMIZATION DETAILS.  ............................................................ 84 
23 REFERENCES  .................................................................................................................... 85 
24 INVESTIGATOR’S AGREE MENT  ................................................................................. 88 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 7 of 88
Tables and Figures  
Figu
re 1: Inhibition of NO production by NA-1 via perturbation of NMDAR- PSD-95 
interactions [Ca=calcium; nNOS=neuronal nitric oxide synthase]  .............................................. 21  
Table 
2-1: Schedule of Assessments ............................................................................................. 17 
Table 10 -1: Definitions of AE- Related Terms .............................................................................. 54 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 8 of 88
1.2 List of Abbr eviations 
3PVO Permanent Occlusion 3 Pial Vessels  
ABC  Airway, Breathing, Circulation  
ADC  Apparent Diffusion Coefficient 
AIS Acute Ischemic Stroke  
ANCOVA  Analysis of Covariance 
ANOVA  Analysis of Variance  
aPTT  Activated Prothrombin Time  
AE Adverse Event  
ASA Acetylsalicylic Acid  
ASPECTS  Albert a Stroke Program Early Computerized Tomography Score  
β-hCG Beta-human Chorionic Gonadotropin 
BI Barthel Index  
BNT  Boston Naming Test 
BP Blood Pressure 
Ca Calcium  
CBC  Complete Blood Count 
CBV  Cerebral Blood Volume 
CFR  Code of Federal Regulations  
CI Confidence Interval  
CRF  Case Report Form  
CRU  Clinical Research Unit  
CT Computed Tomography 
CTA  Computerized Tomographic Angiography (multiphase or dynamic)  
CTP Computerized Tomographic Perfusion 
DWI  Diffusion Weighted Imaging’ 
DVT  Deep Vein Thrombosis 
ECG  Electrocardiogram  
e-CRF Electronic Case Report F orm 
ED Emergency Department  
EDC Electronic Data Capture  
EMA European Medicines Agency 
EVT Endovascular Treatment  
FDA Food and Drug Administration 
FLAIR Fluid Attenuated Inversion Recovery 
HIA Health Information Act 
HIPAA Health Insurance Portability and Accountability Act 
HIV Human Immunodeficiency Virus  
IA Intra -arterial  
ICA Internal Carotid Artery 
ICH Intracranial Hemorrhage 
ICH-GCP Internatio nal Conference on Harmonization- Good Clinical Practice  
IDMC Independent Data Monitoring Committee 
INR International Normalized Ratio  
IOML Inferior Orbitomeatal Line  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 9 of 88
IRB Institutional Review Board  
ITT Intent- to-treat 
IVH Intraventricular Hemorrhage  
IV Intravenous 
LAR  Legally Authorized Representative 
MAP  Mean Arterial Pressure  
MCA  Middle Cerebral Artery  
MCAO Middle Cerebral Artery Occlusion  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocardial Infarction  
MIPS  Maximum Intensity Projections  
MoCA Montreal Cognitive Assessment 
MR Magnetic Resonance  
MRI  Magnetic Resonance Imaging  
mRS  Modified Rankin Scale 
MRP  Magnetic Resonance Perfusion  
Na+ Sodium 
NaCl  Sodium Chloride 
NCCT  Non-contrast Computed Tomography  Scan  
NHPSS  Non-human Primate Stroke Scale  
NIHSS   National Institutes of Health Stroke Scale  
NINDS  National Institute of Neurological Disorders and Stroke 
NMDA  N- methyl D -aspartate
NMDAR  N- methyl D -aspartate Receptor
nNOS  Neuro nal Nitric Oxide Synthase
NO Nitric Oxide
O-F O’Brien -Fleming
OLS Ordinary Least Squares
OR Odds Ratio
PEG Percutaneous Endoscopic Gastrostomy
pH Potential Hydrogen
PI Principal Investigator
PIPEDA Personal Information and Portable Electronic Documents Act
PK Pharmacokinetic
pMCAO Permanent Middle Cerebral Artery Occlusion
PP Per Protocol
PSD-95 Post-synaptic Density 95 Protein
REB Research Ethics Board
RNA Ribonucleic Acid
RR Risk Ratio
SAE Serious Adverse Event
SAH Subarachn oid Hemorrhage
SaO 2 Oxygen Saturation
SAP Statistical Analysis Plan
SBP Systolic Blood Pressure
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 10 of 88 
 SDH  Subdural Hematoma SNAP   Sunnybrook Hemispatial Neglect Procedure 
SOC   System Organ Class  
SOP  Standard Operating Procedures 
SUSAR  Suspected  Unexpected  Serious Adverse Reaction  
TIA  Transient Ischemic Attack  
TICI   Thrombolysis in Cerebral Infarction Score 
TIMI   Thrombolysis in Myocardial Infarction 
tMCAO Transient Middle Cerebral Artery Occlusion  
tPA  Tissue Plasminogen Activator (generic name = alteplase)  
USA/US  The United States of America  
WFNS   World Federation of Neurological Surgeons 
WHO  World Health Organization  
 
  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 11 of 88
2 Study Synopsis  
Trial Objectives  The primary objective is to determine the efficacy of the 
neuroprotectant, NA-1, in reducing global disability in subjects  with 
major acute ischemic stroke (AIS) with a small established infarct core 
and with good collateral circulation selected for  rapid endovascular 
revascularization . 
The secondary  objectives are to determine the efficacy of NA-1 in : 
•Reducing functional dependence
•Improving neurological outcome
•Improving activities of daily living
•Reducing mortality rate
The leading safety objectives are to determine the effect of 
administering a dose of 2.6 mg/kg (up to a maximum dose of 270 mg) 
intravenous (IV) infusion of NA- 1 to subject  with acute stroke who are 
selected for endovascular revascularization on serious adverse events 
(SAEs) and 90 -day mortality.  
Trial Design  This study is a P hase 3, randomized, multi centre , blinded, placebo -
controlled, parallel group, single -dose design . Subjects harboring an 
acute ischemic stroke and who are selected for endovascular 
revascularization in accordance with local institutional practices and 
who harbor a small established infarct core and with good collateral circulation will be given a single, 2.6 mg/kg (up to a maximum dose of 270 mg)  intravenous dose of NA -
1 or placebo as soon as they are 
deemed to have met the enrollment criteria and with the intention of 
starting administration within 30 minutes of randomization. The 
randomization will be by stochast ic minimization  to balance baseline 
factors.  
Subjects  Up to 1120 male and female subject  will be enrolled . 
Inclusion Criteria  
1)Acute ischemic stroke ( AIS) for immediate endovascular treatment
2)Age 18 or greater .
3)Onset (last -seen-well) time to randomization time within 12 hours.
4)Disabling stroke  defined as a baseline National Institutes of Health
Stroke Score ( NIHSS ) > 5 at the time of randomization.
5)Pre-stroke (24 hours prior to stroke onset)  independent functional
status in activities of daily living with modified Barthel Index (BI)
> 90  (95 or 100) .  Patient must be living in their own home,
apartment or seniors lodge where no nursing care is required.
6)Confirmed symptomatic intracranial occlusion, based on multiphaseor dynamic computerized tomographic a ngiography ( CTA ), at one
or more of the following locations: Intracranial  carotid T/L
, M1
middle cerebral artery ( MCA ). Functionally, when defining the M1
or the M2, the bulk of the MCA territory must be ischemic.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 12 of 88
7)Non-contrast computed tomography (NCCT)  and CTA * for trial
eligibility performed or repeated at ESCAPE -NA1  stroke centre
with endovascular suite on- site.
8)Endovascular treatment with declared first endovascular approach
as either stent retriever or aspirat ion device , and intended to be
initiated  (arterial access ) within 60 minutes of baseline /qualifying
NCCT and to first recanalization of 90 minutes.  Study drug
intended to be administered within 60 minutes of the
baseline/qualifying NCCT.
9)Signed informed consent from subject or legally authorized
representative or,  if required to enable inclusion by applicable
national laws and regulations and the applicable independent review
boards/Ethics Committee requirements for obtaining consent , from
the investigator after consultation with an independent physician
who is not otherwise participating in the trial.
*As per the List of Abbreviations ( Section 1.2), all references to CTA
indicate a multiphase or dynamic CTA.
Exclusion Criteria  
1)Evidence of a large core of established infarction  defined as
ASPECTS 0 -4.
2)Evidence of absence of collateral circulation  on CTA  (Collateral
score of 0 or 1).
3)Intent to use any endovascular device other than a stent retrieveror clot aspiration device or intra -
arterial medications as the
initial thrombectomy approach.
4)Intent to use any intravenous thrombolytic other than alteplaseif intravenous thrombolysis is planned.
5)No femoral pulses , very difficult endovascular access  or extreme
tortuosity of great vessels that is predicted to  result in an
inability to deliver timely endovascular therapy .  Direct
common carotid or radial/ brachial/axillary access is permissible.
6) Estimated or known weight > 120 kg or < 45 kg.
7)Pregnancy; if a woman is of childbearing potential a uri ne or
serum beta human chorionic gonadotropin ( β-hCG ) test is
positive , or breastfe eding.
8)Severe contrast allergy or absolute contraindication to iodinatedcontrast  preventing endovascular intervention, including any
contraindications listed in the prescribing information approved
by local authorities (e.g .
, patients with decompensated heart
failure as a contraindication for the use of VISIPAQUETM 270
in Germany).
9)Clinical history, past imaging or clinical judgment suggests that
the intracranial occlusion is chronic  or there is suspected
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 13 of 88
intracranial dissection such that there is a predicted lack of 
success with endovascular intervention. 
10)Prior enrolment in the ESCAPE -NA1  trial or prior receipt of
NA-1 for any reason.
11)Severe known renal impairment defined as requiring dialysis
(hemo - or peritoneal) or if known a creatinine clearance < 29
mL/min.
12)Patient has a severe or fatal comorbid illness that will prevent
improvement or follow- up.
13)Patient cannot complete follow -up treatment due to co -morbid
non-fatal illness  or they are known to be a visitor to the city or
any other known reason for which follow- up would be
impossible  (e.g. incarcerated in a fed eral prison).
14) P articipation in another clinical trial investigating a drug,
medical device, or a medical procedure in the 30 days
preceding study inclusion.
Countries  Canada, Ireland, Sweden , U.S., South Korea , United Kingdom, 
Australia , Germany  
Treatment  NA-1 2.6 mg/kg ( up to a maximum dose of 270 mg , or matching normal 
saline placebo volume) will be administered as a single 10  ± 1 minute 
intravenous infusion in the upper or lower extremity using an infusion 
pump starting after randomization .  All subjects  will undergo attempted 
endovascular recanalization therapy with the intended endovascular 
approach being  either using a stent retriever or clot aspiration device  
and receive best medical care according to modern acute stroke ca re 
guidelines. 
Stent retrievers or aspiration devices will be used according to current 
local jurisdictional guidelines.  
Consent  Signed informed consent will be obtained prior to any protocol -specific 
procedures from the subject or legally authorized representative or,  if 
required to enable inclusion by applicable national laws and regulations 
and the applicable independent review boards/Ethics Committee 
requirements for obtaining consent , from the investigator , after 
consultation with an in dependent physician who is not otherwise 
participating in the trial.   
If the original process involved anyone other than the subject  and if 
required by local standards , consent will be sought for the remaining 
procedures from the subject once they are deemed to have regained 
capacity . 
Randomization 
Method  Treatment will be assigned using 1:1 randomization (placebo:NA -1) 
with a stratification and minimization algorithm to  minimize the 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 14 of 88
contribution of imbalances in baseline factors and non-randomized 
therapies  (e.g., alteplase use) to differences between treatment groups.  
Duration of 
Treatment  This study consists of one 90 -day study period for each subject .   
Subjects will be hospitalized for care after their acute stroke according 
to the current standard of care.  Subjects are required to return to clinic 
on Days 30 and 90 for end -of-study procedures.   
Laboratory 
Tests  In order to support the assessment of patient safety baseline ( pre-dose) 
and post dose hematology and chemistry laboratory tests  will be 
collected .  
At baseline , and at 24 ± 12 hours after study drug infusion and 
termination of EVT  blood work will be evaluated which include : 
complete blood count ( CBC ), electrolytes,  international normalized 
ratio (INR), activated prothrombin time ( aPTT ), serum c reatinine and 
serum glucose. 
Other laboratory or point-of- care testing may be performed at the 
discretion of the attending physicians and team.  
If the subject is female and is of childbearing potential, a pregnancy test 
(urine  or serum point-of- care pregnancy test) must be completed  and a 
negative test  result  obtained prior to inclusion in the trial. 
Electrocardiograms will also be collected and reviewed at baseline (pre-
dose, unless impeding access to timely intervention ) and at 24 hours. 
Assessment of 
Efficacy  and 
Power  The primary efficacy outcome variable for the pivotal assessment of 
efficacy for regulatory submission purposes is the overall proportion of subjects experiencing a favorable functional outcome 90 days post -
randomization, defined as a score of 0 to 2 on the modified Rankin Scale 
(mRS). These subject s are defined to be responders.  Assuming a 52% 
overall responder rate for the placebo group, there will be an 
approximately  80% power to detect an 8.7% absolute effect difference 
between response rate (proportio n of responders, with Day 90 mRS in 
the range 0 to 2) with NA -1 and placebo, at alpha level 0.05, 2- sided  
with a planned sample size of 1076 evaluable subjects, randomized 1:1, per group, accounting for a single interim analysis when 600 subjects 
have completed their 90 day follow up visit  information ( 600 subject s 
with primary endpoint assessments) with O’Brien -Fleming alpha -
spending function stopping boundary for overwhelming e fficacy and a 
non-binding 1% conditional power futility stopping boundary  (EaST® 
V6.3) . The sample size will be inflated approximately 4% to N= 560 per 
group to account for loss- to-follow-up and drop-outs.  
The primary hypothesis to be tested is that administration of NA- 1 will 
result in an increase in the proportion of subjects with independent 
functioning on the mRS (as defined by a score of 0 -2) at Day 90.  The 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 15 of 88
primary analysis will be a Wald test for treatment group difference in 
the primary outcome from a logistic regression including treatment and 
the following important prognostic factors : intravenous alteplase 
treatment , intended initial endovascular approach as well as a ge, sex 
baseline NIHSS score , baseline ASPECTS  score, occlusion location and 
site.  
The primary efficacy analysis  and secondary endpoint analyses  will be 
conducted on the intent- to-treat ( ITT) population, defined as all subjects 
randomized into the trial with grouping by randomized treatment, 
regardless of treatment actually received.  Deceased subject s will be 
included in the ITT population with a mRS score of 6.  
A key secondary outcome analysis is planned to evaluate a shift of one 
or more categories to reduced functional dependence analyzed across 
the whole distribution of scores on the mRS at Day 90 or the last rating . 
This secondary outcome will be an  adjusted analysis using  a 
proportional odds model to derive the common odds of improvement (“shift”) along the mRS scale.   
Adjustment will include all of the 
variables  used i n stratification (intravenous alteplase treatment, 
intended initial endovascular approach) and  in the minimization 
algorithm (age, sex, baseline NIHSS score, baseline ASPECTS score, 
occlusion location, and site) . The proportional odds assumption will be 
tested . 
Other secondary outcomes include: 
1)Proportion of subjects with good neurological outcome, as
defined by a score of 0 -2 on the NIHSS at Day 90 or the last
rating.
2)Proportion of subjects with functional independence in activitiesof daily living, as defined by a score of ≥ 95 on the BI at Day 90
or the last rating.
3)A reduction in mortality rate, as defined by e vent rate (%) for
mortality over the 90 day study period
4) Proportion of subjects with functional independence, as defined
by a score of 0 -1 on the mRS at Day 90 or the last rating.
Assessment of 
Safety  For the safety analysis, the frequency of SAEs, 90 -day mortality, 
adverse events (AEs), discontinuations due t o AEs .  As well , baseline 
and post-dose study drug  vital signs, laboratory  (hematology and 
chemistry)  and electrocardiogram (ECG) findings will be analyzed.   
Independent 
Data Monitoring Committee  An Independent Data Monitoring Committee (IDMC) will perfo rm 
periodic safety reviews of the clinical data. The reviews will occur once 100, 300 and 600 subject s 
have reached their Day 90 final study visit. 
An efficacy interim analysis (after approximately 600 subjects complete 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 16 of 88
the Day 90 follow -up) will be conducted using the alpha spending 
function method1 with O’Bri en and Fleming2 type stopping boundary 
for efficacy and a non- binding conditional power boundary for futility. 
The trial may be stopped for overwhelming efficacy  or futility  at the 
interim analysis if the test statistic crosses the  O’Brien -Fleming (O -F) 
or conditional power boundary.  
Bioanalytical 
Method s The plasma concentrations  (immunogenicity)  of NA -1 from a subset of 
up to 250 s ubjects  from sites located in Canada and the USA will be 
analyzed using a validated direct ELISA assay method. 
Pharmacokinetic assessments from a subject of up to 100 subjects from 
a subset of sites located in Canada and the USA will be evaluated . 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 17 of 88
Table 2-1: Schedule of Assessments  
Baseline  Post-
EVT  
(~2 h)  Day 1  
(24 ± 12 h 
from random -
ization)  Day 2  
(48 ± 8 h from 
randomization)  Day 5 or 
discharge 
(±1 d)  Day 30  
(±5 d)  Day 
90 
(±14 
d) 
Informed consent  X 
Attempt at  regained capacity 
informed consent★ X X X X X 
History and examination  X 
Weight  X* X (Actual)  
Vital Signs (BP, HR, Temp) ★★X X X X X 
Randomization/ Study drug 
administration  X 
Mortality  X X X 
NIHSS  X X X X X X X 
mRS  X¶ X X X 
Barthel Index  X X X 
BNT15, SNAP, MoCA¶¶ X 
EQ-5D-5L X X 
NCCT head  X 
CTA (Circle of Willis) X 
Endovascular Procedure  X 
MR head  X** 
CBC   (hemoglobin, platelets 
and hematocrit) , elect rolytes  
(sodium, potassium, chloride) , 
INR, aPTT, serum creatinine 
and serum glucose  X‡ X 
Pregnancy test  X‡‡ 
Immunogenicity sample ‡‡‡ X X 
Pharmacokinetic samples ‡‡‡‡ X 
ECG  X§ X 
AE assessment  Collected to Day 30 visit  
SAE assessment  Collected to Day 90 visit  
Prior medications  X§§
Concomitant medications  Collected to Day 30 visit  
★If the original process involved anyone other than the subject  (and if required) , site staff will make ongoing efforts until (1) regained
capacity consent is obtained from subject , (2) death, or (3) completion of the Day 90 assessment.
★★Vitals signs (BP, HR only) should be recorded immediately before and after completion of the study drug infusion, temperature  will
be taken at baseline per standard of care.
¶ Historical (pre -stroke) mRS score can be collected at any time and will be reported on the 24h CRF .
¶¶ Assessments will be conducted only if the tool/scale is available in local language.
* At baseline estimated or actual weight**Day 1 MR head may be supplanted by an NCCT hea d if MR is unavailable  or contraindicated .
‡ Blood should be drawn at baseline, but results are not required prior to randomization.
§For ECG, if treating physician deems that pre -treatment ECG impedes access to timely care, ECG must be completed within 6 hours  
of randomization.
‡‡ If the subject  is female and is of childbearing potential a pregnancy test (urine or serum point -of-care pregnancy test) must be
completed and the result must be negative; this is the only mandatory lab oratory test prior to randomization.
‡‡‡ Immunogenicity samples will be taken from a subset of up to 250 subjects  at Canadian and US sites only.
‡‡‡‡ PK samples will be taken from up to 100 subjects at a subset of Canadian and US sites.  Samples will be taken at pre-dose and at
10, 20, 30, 60 and 12 0 min after the start of drug administration .
§§Prior medications should be documented but their documentation not required prior to randomizati on.
d = days; h = hours
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 18 of 88
3 Coordinating Centre, Sponsor, Investigators and Facilities 
Coordinating Centre  University of Calgary  
Foothills Medical Center  
1403 29th Street NW 
Calgary, AB T2N 2T9 
Sponsor:  NoNO Inc  
Krembil Research Institute 
8KD-406 60 Leonard Avenue Toronto, ON Canada M5T 2S8 
Sponsor Medical Oversight:  Michael Tymianski, M.D., Ph.D., F.R.C.S.C.  
Project Director:  
Senior Project Leader  
Overall Coordinating 
Investigator: 
Co-Coordinating 
Investigators President and CEO, NoNO Inc. 
NoNO Inc 
NoNO Inc 
Michael D. Hill M.D., MSc, F.R.C.P.C. 
Director, Calgary Stroke Unit  
University 
of Calgary 
Mayank Goyal, M.D., F.R.C.P.C. 
Director of Research, Department of Diagnostic Imaging 
Bijoy K. Menon, MD, DM, MSc 
Assistant
 Professor Departments of Clinical Neurosciences, 
Radiology and Community Health Sciences 
redacted
redacted
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 19 of 88
Data Management Center:  
Imaging Management 
Centre:  Clinical Research Unit (CRU) 
University o
f Calgary 
Calgary Image Processing  and Analysis  Center ( CIPAC), 
University o
f Calgary 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 20 of 88
4 BACKGROUND INFORMATION 
4.1 Rationale  
The rationale fo r this study is the following:  
1)There is no convincing  evidence from randomized controlled trials that neuroprotection can be
of clinical benefit to pat ients with AIS .   There is however, extensive preclinical evidence that
neuroprotection is of greatest benefit for improving functional outcome in studies employing
experimental animal stroke models in which  stroke is followed by reperfusion, as compared
with str oke models in which arterial vessel occlusion is undertaken without reperfusion.
2)The ESCAPE and other recent trials of endovascular thrombectomy for AIS  have demonstrated
that modern acute endovascula r therapy can rapidly recanalize blocked major arteries in
patients with acute stroke arising from large artery occlusion with a low  complication rate  and
high complete reperfusion rates .3-7  This paradigm replicates  the preclinical animal ischemia -
reperfusio n models in which neuroprotectants have the highest demonstrated efficacy.
3)The neuroprotectant, NA-1, has been demonstrated to be highly effective in reducing stroke
size and improving the functional outcome of experimental animals subjected to acute stroke,
including rats and primates. NA -1 is more effective in reducing infarct size and improving
functional outcome in models of ischemia -reperfusion, as compared with permanent arterial
occlusion8,9,10.
4)NA-1 has an excellent safety profile in precl inical animal studies, a human Phase 1 trial, and a
human P hase 2 study (the ENACT trial).11 Patients in the ENACT trial were also individuals
who were being subjected to an endovascular procedure (intracranial aneurysm repair) and to
treatment with NA -1 or placebo.
5)NA-1 is the only neuroprotectant to have been shown to reduce ischem ic brain damage in
humans having demographics similar to those of stroke patients.
6)The inclusion/exclusi on criteria of the ESCAPE trial3 were successful in identifying patients
with salvageable brain  (an ischemic penumbra) . Modern endovascular techniques have
extremely high rates of safe and effective reperfusion. This  makes  the ESCAPE patient
selection process and use of endovascular recanalization an ideal clinical paradigm to replicate
prior preclinical animal studies that support the effectiveness of the neuroprotectant, NA-1.
7)There is a compelling need to develop neuroprotectants in order to increase the proportion of
patients who may benefit from recanalization therapies. These agents could improve the
outcomes of those who receive endovascular recanalization, and make more patients intocandidates for endovascular or pharmacological recanalization treatments.
4.2 The Neuroprotectant , NA-1 
NA-1 is a synthetic , cell -permeant  eicos apeptide (20 amino acids)  that perturbs protein-protein 
interactions on the cytosolic surface of the cell membrane mediated by post- synaptic density 95 
protein (P SD-95)
12, an abundant protein localized in post -synaptic densities of central nervous 
system neurons .  It may provide significant benefit for the treatment of acute cerebral ischemia if 
administered to stroke patients who present to medical attention before infarction is comple te. The 
rapid progression of irreversible brain injury in most acute strokes  implies a short window of 
clinical efficacy of any treatment, including NA-1.  The ability to identify patients with salvageable 
brain using the criteria  used in the ESCAPE trial provides an opportunity to target patients who 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 21 of 88
may have the greatest benefit from neuroprotection, and to enhance further the impact of 
reperfusion therapies3. Our preclinical and clinical data support this notion. 
NA-1 is composed of two parts: a 9- amino acid active substance that binds to PSD -95, and an 11 -
amino acid sequence derived from the human immunodeficiency virus ( HIV)-1 Tat protein which 
permits NA -1 to penetrate through the blood- brain barrier and enter neuronal target cells.  PSD -
95 couple s transmembrane proteins such as the N -methyl-D- aspartate (NMDA) subtype of 
glutamate receptors to various intracellular signaling enzymes  that mediate the neurotoxic sequelae 
of NMDA receptor activity. Specifically, NA-1 inhibit s the interaction between PSD -95 and the 
GluN2B  subunit of the NMDA receptor (NMDAR) , thus uncoupling NMDARs from downstream 
neurotoxic signaling enzymes and prevent ing or limiting the onset of excitotoxicity that is 
associat ed with AIS  (Figure 1). NA -1 has no known effect on the electrophysiological aspects of 
NMDAR channel function, but results in decreases in pro-death signals downstream of NMDARs 
such as reduced production of the toxic free radical nitric oxide (NO). 13 
Figu
re 1: Inhibition of NO production by NA -1 via perturbation of NMDAR -PSD-95 interactions  
[Ca=calcium; nNOS=neuronal nitric oxide synthase ] 
4.3 Summary from Nonclinical Studies and Clinical Trials  
NA-1 has been shown to be a promising neuroprotectant in rats and in non- human primates 
exposed to experimental strokes when it is administered within three  hours of stroke onset8,13. It is 
also effective in reducing iatrogenic stroke burden in humans subjected to endovascular aneurysm 
repair as measured by a reduction in the number of new lesions visualized by magnetic resonance imaging (MRI )
11. In the human study, NA -1 was administered on average within two hours after 
initiation of the aneurysm repair procedure. These preclinical and clinical findings are consistent with the well- established notion that there must still be brain left to salvage in order for any 
neuroprotectant to result in a benefit to patients with AIS
14. All these studies had in common the 
fact that NA -1 was administered in a paradigm in which stroke damage was not yet complete. See 
Figure 1: Inhibition of NO production by NA -1 via perturbation of NMDAR -PSD -95 
interactions  [Ca=calcium; nNOS=neuronal nitric oxide synthase]  

NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 22 of 88
4.3.1 Nonclinical Studies  
4.3.1.1 NA-1 Effect on Infarct Size and Volume in Rodent Models of Stroke 
Several in vivo  pharmacology studies have been conducted with NA -1 in rodents to evaluate the 
effect of NA -1 on infarct size and volume in models of stroke involving either transient or 
permanent occlusion of intracranial arteries, and effects on sensory, emotio nal, and cognitive 
deficits.  The results of the rodent studies demonstrated that NA -1 is delivered to the brain of an 
intact animal following systemic exposure via intravenous administration, and also appears to 
accumulate at sites of brain injury when given intravenous ly after animals had been subjected to a 
cortical stroke induced by permanent occlusion 3 pial vessels (3PVO model)9. When administered 
intravenously , post -insult treatment with NA -1 (0.08 to 7.60 mg/kg) in a transient stroke model 
produced by middle cerebral artery occlusion (tMCAO) is effective in both permanently reducing 
stroke size, and in improving neurological function even when treatment is administered as late as three hours after stroke onset. There was no effect on normal central nervous system function. Rats 
treated with NA -1 had reduced motor, sensory, emot ional, and cognitive deficits, as well as faster 
recovery of pre -surgery weight. NA-1 has been shown to be efficacious in models of permanent 
stroke in rats at a dose of 7.6 mg/kg when administered one -hour post -insult
9. Furthermore, Fisher 
and colleagues found that administration of NA -1 in a rat model of permanent m iddle cerebral 
artery occlusion (pMCAO) “froze” the ischemic penumbra measured using MRI15. In other words, 
NA-1 administration in the face of an evolving ischemic injury halted the progression of further 
brain damage as of the time it was administered.  
4.3.1.2 Effect of NA -1 in Reperfused  MCAO Model of AIS in Non- Human Primates (30- Day 
Study)  
To test whether NA -1 is neuroprotective in acute AIS in a gyrencephalic species, a blinded, 
randomized trial of NA -1 versus drug vehicle in a tMCAO model in 20 cynomolgus macaques was 
completed8. NA-1 2.6 mg/kg or drug vehicle were administered in blinded fashion 60 minutes  
following middle cerebral artery occlusion (MCAO). The MCA  was reperfused 90 minutes 
following occlusion. Stroke volume on 24 hour MRI diffusion weighted imaging (DWI) was statistically significantly reduced by over 50% in NA -1-treated animals as compared  with placebo 
animals and this effect was maintained on the Day 30 MRI. There was also a significant improvement in Non- Human Primate Stroke Score (NHPSS) and significant improvements in 
sensory and motor function. 
There were no differences in any of the p hysiological parameters [including mean arterial pressure 
(MAP)] for NA -1 and placebo treated animals, with the exception of temperature at the time of 
MRI completion (36.5
oC ± 0.27 in placebo treated animals versus 37.4oC ± 0.16 in NA -1 treated 
animals, p =0.015).   
4.3.1.3 Effects of NA -1 on Infarct Volume and Gene Transcription Response in pMCAO 
Model of AIS in Cynomolgus Macaques 
To test the neuroprotective effect of NA -1 on infarct volume and gene transcription response, six 
macaques underwent pMCAO, with NA -1 or placebo treatment administered five minutes after 
ischemia onset.   DWI MRI scans were taken every 15 minutes. The volume of brain in which 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 23 of 88
DWI hyperintensity was detectable increased over time in both groups.  However, treatment with 
NA-1 attenuated t he rate of this increase by about twofold (p=0.019).  Moreover, within the 
ischemic volume, DWI intensity in brains of NA -1-treated animals remained lower than that of 
untreated controls, suggesting that tissue within the infarct volume maintained better i ntegrity8. 
Tissue was collected from the ischemic penumbras (adjacent to i nfarcted tissue) and from 
corresponding sites in the contralateral non- ischemic hemisphere at one and six hours after 
ischemia onset. Ribonucleic acid (RNA) was extracted and hybridized to whole -genome macaque 
arrays. Differential gene expression analysis revealed that treatment with NA -1 resulted in a lower 
proportion of down regulated genes and preservation of the capacity to up regulate  genes at both 
one and six hours after stroke.  Overall, the genome -wide survey suggested that neuroprotection 
with NA-1 preserved cellular functionality as gauged by the capacity for gene transcription in 
ischemic brain tissue8. 
4.3.1.4 Effect of NA -1 in Prolonged tMCAO Model of AIS (7- Day Study)  
The hypothesis that NA -1, administered one hour into a 4.5 hour tMCAO in cynomolgus macaques 
(which is the limit of effectiveness of alteplase in a human reperfusion study16) would improve 
stroke neurological outcomes and reduce stroke volumes seven days following stroke  was tested . 
Six animals received NA -1 (2.6 mg/kg IV) and six received placebo one hour following MCAO. 
The MCA was reperfused 4.5 hours after MCAO.  There was a significant reduction in stroke volume ( relative reduction of 25%) in the NA -1 group in comparison with the placebo group. 
Scores on the NHPSS we re significantly improved in NA -1 treated animals at seven days
8. There 
were no differences in any of the physiological parameters (including MAP) at any of the measured 
time points for the NA -1 versus placebo treated animals.   
4.3.1.5 Effect of NA -1 Administered Three Hours After Onset of 3.5 Hour t MCAO in 
Cynomolgus Macaques (14- Day Study)  
To test whether NA -1 is beneficial when administered later in the setting of a prolonged tMCAO, 
24 cynomolgus macaques received a 10- minute infusion of NA -1 or placebo three hours after the 
onset of a 3.5 hour tMCAO.  There were no mortalities.  Final imaging and neurological assessments were conducted at 14 days.  NA -1 treated animals exhibited significant reductions in 
infarct volumes as compared with placebo as evaluated on MRI (T2- weighted MRI:  at 48 hours: 
p=0.006; DWI MRI at 48 hours: p=0.004;  T2-weighted MRI at 14 Days: p=0.003).   Animals 
treated with NA -1 exhibited improved NHPSS scores throughout the 14- day observation period 
days [p=0.004, two- way repeated measures analysis of variance (ANOVA)] and trended to better 
performance in the six -well and the valley staircase tasks
8. There were no statistically signific ant 
differences in any of the physiological parameters (including MAP) at any of the measured time points for the NA-1 versus placebo treated animals.    
We have reviewed the outcomes using analyses analogous to those proposed in the current 
protocol, but using the available NHPSS scores instead of the mRS scores prop osed in this current 
trial. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 24 of 88
Analogous to our proposed analysis of the primary outcome using a dichotomy approach, the 
NHPSS was divided in a binary fashion defining good outcome as NHPSS 0- 2 at 14 days.  With 
this, we calculated the risk ratio ( RR) = 3.0 (0.7-12.0), p = 0.193, with an absolute risk difference 
of:  0.33 (CI 95 -0.02 – 0.69). Alternatively, using simple ordinary least squares  (OLS)  linear 
regression, NHPSS = -3.5*trt + 6.9, p (β-coeff) = 0.005.  So on average at 14 days , the NHPSS wa s 
3.5 points less in the treated group. 
By analogy  to one of our proposed 
secondary analyses using a proportional 
odds model (‘shift analysis’), we presented  the outcome on the NHPSS 
divided in quartiles at 14 days.  Note that the NHPSS shift here is calculated by quartiles of NHPSS and not by pre -
specifi ed groups.  
Common odds ratio ( OR; (proportional 
odds model) for shift along the NHPSS = 8.1 [Confidence Interval ( CI)
95 1.5-
45.3)], p = 0.016. 
4.3.1.6 Eff
icacy of NA -1 in Reducing the Number and Volumes of MRI -visible Strokes in a 
Cynomolgus Macaque Model of Mic ro-embolic Stroke 
A study of the efficacy of NA -1 in reducing the number and volume of MRI -visible strokes in a 
cynomolgus macaque model of microembolic stroke was completed10. The purpose of the study 
was to evaluate NA -1 in an experimental setting that mimics the MRI -detectable strokes sustained 
by human patients as a result of endovascular brain aneurysm repair. The study evaluated the effects of an intravenous dose of NA -1 2.6 mg/kg on the volume and number of cerebral infarcts 
produced by an intra -arterial injection of 20 100μm polystyrene spheres in cynomolgus macaque 
monkeys, an experimental embolic stroke paradigm that produces a permanent occlusion of the affected brain  vessels.  
Ten cynomolgus macaques were randomized to receive NA -1 2.6 mg/kg or placebo. Following 
induction of anesthesia, each animal underwent insertion of a femoral angiography catheter and a cerebral angiogram was performed. Each animal then received an injection of 20 100μm polystyrene sphere emboli. At one hour following the embolic procedure, NA -1 (2.6 mg/kg) or 
placebo [equivalent volume of 0.9% sodium chloride (NaCl)] was infused intravenously in 5 mL 
of 0.9% NaCl over 10 minutes. Animals underwent  diffusion and T2- weighted imaging at four 
hours after the injection of emboli. Twenty -four hours after the embolic procedure, the animals 
were re- anesthetized and returned to the MRI scanner for further DWI and T2 imaging. A further 
MRI at four weeks was utilized to confirm that DWI hyperintensities had resolved completely. 
After this 4 -week washout period, each animal was crossed over to the opposite treatment group 
and the experiment was repeated.  

NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 25 of 88
All 10 animals completed the first iteration of the cros sover trial. On the second round, three 
animals were lost due to an air embolus in a placebo animal, a post -operative aspiration in a 
placebo animal, and an anesthetic related cardiac arrest preceding surgery and dosing in the third. 
There were no significant differences in physiologic parameters between groups (including MAP). Animals treated with NA -1 exhibited markedly reduced stroke numbers and volumes as compared 
with placebo -treated animals. Numbers of total strokes were: 4.7 ± 0.16 and 12.75 ± 0.15 i n NA -
1 versus placebo respectively (p<0.001). Volumes of total strokes were: 28.4 ± 2.98 and 64.4 ± 3.41 in NA-1 versus placebo respectively (p = 0.015).  
This study revealed that counting the number and/or volume of new, small lesions incurred by 
small in tra-arterial emboli is a useful bio -assay that can detect the consequences of penetration of 
a study drug into target brain tissue and to measure its intended biological effect on reducing stroke damage.  
4.3.1.7 Nonclinical Primary Pharmacology Summary 
In summary , NA -1 is a novel peptide that has now been repeatedly shown to protect 
against ischemic damage following stroke in several rodent and non-human primate models. NA-1 targets intracellular protein interactions downstream of glutamate receptors, thus acting  via a 
novel mechanism. Studies have demonstrated that, in addition, NA -1 does not affect the 
electrophysiological function of NMDAR channels. Therefore, unlike NMDA receptor antagonists, NA -1 is in a class of drugs that is not anticipated to have negative  side effects that 
were ascribed to glutamate receptor antagonists.    
4.3.2 Clinical Trials  
4.3.2.1 Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT) Trial 
To test the feasibility of neuroprotection in the human brain based on the results in the non-human primate microembolic stroke study described above, a Phase 2 multi centre , randomized, fasting, 
double- blind, placebo- controlled, safety, tolerability, and efficacy study evaluating a single dose 
of intravenous NA-1 was recently completed in male and female patients undergoing endovascular 
repair of brain aneurysms (unruptured and ruptured)
11. The primary objectives of the trial were to 
determine the safety and tolerability of a single intravenous dose of NA -1 (2.6 mg/kg) and the 
efficacy of NA -1 in reducing the volume of embolic strokes as measured by MRI imaging. The 
secondary objectives were to determine the efficacy of NA -1 in reducing the number of embolic 
strokes; procedurally -induced vascular cognitive impairment as measured by a battery of cognitive 
tests; and the frequency of large embolic strokes.  The stu dy consisted of one 30- day ev aluation  
period.  
A total of 185 subjects were enrolled in the study; 92 were dosed with NA -1 and 93 with placebo. 
In the NA -1 treatment group, 74 subjects (80%) had unruptured aneurysms on study entry and 18 
(20%) were ruptured. The placebo group had 74 (80%) subjects with unruptured aneurysms and 
19 (20%) with ruptured aneurysms.  Six subjects (3.2%) did not complete the study: Two subjects died (both in the placebo group), one experienced an AE eventually leading to death (in the NA-1 group), two were lost to follow -up (in the NA -1 group), and one was discontinued due to protocol 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 26 of 88
non-compliance (failed to show up for the scheduled Day 30 visit; in the placebo group).  Of 185 
randomized subjects, 184 completed the post-procedure MRI scan (12-96 hours).    
Overall, NA -1 reduced the mean number of lesions by three new lesions as evaluated by DWI 
(p=0.018) and by two new lesions as evaluated by fluid- attenuated inversion recovery (FLAIR; 
p=0.048) in comparison with placebo in All Randomized Subjects (subjects receiving any amount 
of study drug).  The distribution of the volumes of new strokes was highly skewed, and did not follow a normal distribution. This was anticipated based on the non- human primate model of 
microembolic stroke study
10. The median lesion volume was less than 1,000 mm3. Two  subjects 
with unruptured aneurysms exhibited large strokes (10,702 and 49,204 mm3 by DWI volume) as 
a result of peri -procedural complications of endovascular repair, and both were in the NA -1 group. 
In both cases the major ischemic stroke occurred several hours after the procedure. The first patient was neurologically well for several hours post -procedure (placement of a Pipeline stent for a giant 
cavernous carotid aneurysm) and then developed aphasia. The second patient was neurologically 
well until the morning after his procedure (balloon- assisted coiling of an internal carotid artery 
aneurysm) when he developed right hemiparesis. Both had been treated with double antiplatelet 
therapy [acetylsalicylic acid (ASA) and clopidogrel].  Due to these two outlie rs, there was 
sufficient distortion of the mean volume of strokes in the NA -1 group such that the analysis of the 
impact of NA -1 on mean lesion volume was neutral in the analysis of all r andomized subjects and 
only subjects with unruptured a neurysms . When subjects with s trokes < 10 cc were considered 
(i.e., when the two outliers were excluded from analysis), a halving of lesion volume was observed in patients treated with NA -1. This effect was even more evident when the results were adjusted 
for the following pre -specified covariates: age, aneurysm status, use of adjunctive devices, groin 
puncture to infusion time, and the use of antiplatelet agents (p=0.009 for DWI and p=0.014 for  
FLAIR). Among the subgroup of subjects with ruptured aneurysms, NA -1 treatmen t reduced the 
volume of FLAIR and DWI lesions (FLAIR: p=0.023; DWI: p=0.015) and the number of FLAIR and DWI lesions (FLAIR: p=0.046; DWI p=0.027).   
In terms of neurological outcomes at Day 30, there were no differences between the proportion of 
all randomized s ubjects with good outcomes (score of 0- 1) on the NIHSS in the NA -1 and placebo 
groups at Day 30. Similarly, there were no differences between the proportion of subjects with independent functioning (score of 0- 2) on the mRS in the NA -1 and placebo groups at Day 30. 
This was as expected because subjects that met the eligibility criteria were generally neurologically intact (unruptured aneurysms), or were of a good World Federation of Neurological Surgeons (WFNS) subarachnoid hemorrhage (SAH) grade (ruptured aneurysms). Baseline NIHSS and mRS scores were consistent with low levels of neurological impairment and disability (median NIHSS and mRS of 0), which leads to a floor effect in scale sensitivity. However, in the subjects with 
ruptured a neurysms (a subgroup with anticipated neurological impairments) treatment with NA -1 
significantly increased the proportion of subjects with a good outcome on the NIHSS versus placebo  at the 30 -day follow -up (100.0% versus 68.4%, respectively; p=0.020).  This was not 
accounted for by differences in post- treatment SAEs such as hydrocephalus, the need for cerebral 
spinal fluid diversion, or cardiopulmonary complications. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 27 of 88
4.4 Summary of Known Potential Risks and Benefits  
4.4.1 Phase 1 Study  
A Phase 1, randomized, fasting, double -blind, placebo -controlled, safety, tolerability, and 
pharmacokinetic study evaluated single ascending doses of intravenous NA-1 in healthy male and 
post- menopausal or surgically sterile female human subjects (Biovail Contract Research Study 
3301). The primary objectives of this study were to determine the safety and tolerability of single 
ascending intravenous doses of NA -1.  Sixty -two normal, healthy, non -smoking male and post -
menopausal or surgically sterile female s ubjects were dosed in eight cohorts. Subjects received a 
single dose of NA -1 or placebo on Day 1 of the study period, according to a randomization scheme. 
NA-1 was given as follows, with the dose increasing per cohort: 0.02, 0.08, 0.20, 0.375, 0.75, 1.50,  
2.6 and 3.75 mg/kg of active drug, given as a 10 ± 1 minute intravenous infusion.  Subjects were 
required to return on Days 7, 14 and 28 for interim and end-of- study procedures.  There were no 
SAEs; the majority of noted AEs were mild in severity; no subj ects failed to complete the study 
protocol; and no subjects withdrew from the study. Forty subjects experienced a total of 168 AEs. Thirty -four of the 46 active treated subjects (73.9%) experienced at least one AE, while six of 16 
placebo treated subjects  (37.5%) experienced at least one AE.  Of the 168 AEs, 103 were listed as 
probably related to the study drug and five AEs were possibly related to the study drug.  No severe AEs were reported while 160 of the 168 AEs were mild in severity and eight were moderate in severity. The most commonly reported AEs in subjects receiving any dose of NA -1 were flushing 
(22% of subjects), dry mouth (20%), feeling hot (20%), dizziness (17%), localized pruritis (15%), decreased blood pressure ( BP;11%), generalized rash (9%), generalized erythema (9%), nausea 
(9%), increased blood glucose (9%), increased alanine aminotransferase (9%), oral hypoaesthesia (9%), paraesthesia (9%), generalized pruritis (7%), urine positive for white blood cells (7%), and localized rash (7%). The incidence of AEs in the 30 subjects receiving NA -1 at dose levels of 0.02, 
0.08, 0.20, 0.375, 0.75 and 1.50 mg/kg was the same as that of the 16 placebo treatment subjects. Subjects in the 2.6 and 3.75 mg/kg dose groups experienced more AEs than subjects  in the lower 
dose groups, though none was serious.  Overall, NA -1 was well tolerated as a single intravenous 
dose in the range of 0.02 to 2.6 mg/kg, administered to healthy male and post- menopausal or 
surgically sterile female subjects.  
4.4.2 Phase 2 Study (ENACT)  
The Phase 2 ENACT study investigated the effect of a single intravenous dose of NA -1 2.6 mg/kg 
on reducing the volume and number of embolic strokes caused by the aneurysm repair procedure and in increasing the proportion of subjects with a good clinical outcome in 185 patients undergoing endovascular aneurysm coiling of unruptured or ruptured aneurysms
17. In total, 724 
treatment -emergent AEs were reported in 168 (91%) of all randomized subjects.   A total of 388 
AEs were report ed in 85 of 93 subjects who received placebo (91%) and 336 AEs were reported 
in 83 of 92 subjects who received NA -1 (90%). The most frequently -reported individual AEs were: 
headache, reported in 40% of placebo subjects and 46% in NA-1 subjects; nausea (29% and 36%, respectively), vomiting (9% and 13%), procedural pain (11% and 2%; p=0.018), and hypotension (6% and 10%).  Of the 388 events reported in placebo subjects, 208 (54%) were mild, 159 (41%) were moderate and 21 (5%) were severe.  Of the 336 AEs repo rted in NA -1 subjects, 187 (56%) 
were mild, 121 (36%) were moderate and 28 (8%) were severe. Of the 388 AEs reported in placebo 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 28 of 88
subjects, 271 (70%) were unrelated, 96 (25%) were unlikely related, 21 (5%) were possibly related 
and 0 (0%) were probably relat ed. Of the 336 AEs reported in NA -1 subjects, 251 (75%) were 
unrelated, 72 (21%) were unlikely related, 11 (3%) were possibly related and 2 (1%) were probably related.  There were three deaths during this study, two in the placebo group and one in the NA -1 
group.  The SAEs leading to death were all severe and unrelated to study drug.  Other than these three deaths, there were no other discontinuations due to AEs.  There were 35 SAEs in 23 subjects: 24 SAEs in 14 placebo subjects and 11 SAEs in nine NA -1 subjects.  None of the SAEs were 
assessed as related to study drug.  Overall, there were very few abnormal clinically significant Hematology and Biochemistry results in both treatment groups. There were no noteworthy differences across time between treatment  groups for any of the laboratory parameters. One 
placebo subject (1%) had an elevated histamine level postdose (16 nmol/L) versus five NA -1 
subjects (5%) ranging from 10 -15 nmol/L (normal range for males and females ≤ 10 nmol/L).  In 
terms of vital signs,  there were no noteworthy findings in mean heart rate across time between 
treatment groups.  There were very few abnormal clinically significant 12 -lead ECG results in the 
NA-1 and placebo groups.  There were no cardiac AEs that were considered to be an SA E or 
significant AE in either treatment group.  Cardiac AEs were infrequent in both treatment groups. Overall, NA -1 2.6 mg/kg was well tolerated and no safety concerns were identified in any of the 
patient groups. 
4.4.3 Summary of Safety of NA-1 
Overall, NA -1 administered as a single intravenous dose was well tolerated at doses up to and 
including 2.6 mg/kg, and no safety concerns have been identified in any of the patient groups in 
the clinical trials.  
4.5 Des
cription of and Justification for the Route of Administration, Dosage, Dosage 
Regimen and Treatment Period  
NA-1 2.6 mg/kg , up to a maximum of 270 mg  (or matching placebo volume) is administer ed as a 
single approximately 10 -minute intravenous infusion in the upper or lower extremity using an 
infusion pump initiated in the CT scan suite.  The 2.6 mg/kg dose was chosen for this clinical trial 
because of (1) the safety profile observed in the previous Phase 1 and 2 clinical trials, (2) the 
observed capacity of this dose of NA -1 to reduce stroke tissue damage and to improve neurological 
function in rats and non- human primates exposed to experimental strokes when NA -1 was 
administered in animals exhibiting salvageable brain , and (3) the capacity of this dose to reduce 
stroke tissue damage and improve neurological damage in human subjects undergoing endovascular repair of brain aneurysms.  
4.6 Target Patient Selection  
Inclusion/exclusion criteria of all prior neuroprotection trials aimed at selecting subject  who would 
respond to the neuroprotective study drug. Preclinical evidence indicates that neuroprotection is 
aimed at salvaging brain in the ischemic penumbra, defined as that part of the ischemic brain that can be prevented from progressing to infarction if an appropriate treatment is given. However, due to the failure of all prior neuroprotection trials, it is unclear whether the prior criteria used for 
selecting responders were appropriate.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 29 of 88
The ESCAPE trial provides an unprecedented opportunity for testing neuroprotectants because its 
inclusion/exclusion criter ia have successfully defined a patient population in whom brain salvage 
was achievable. This is therefore a de-facto patient population which is most likely to exhibit an 
ischemic penumbra, the target for neuroprotection, at the time of initiation of endovascular recanalization therapy. Additionally, the high rates of reperfusion achieved with endovascular recanalization recapitulate ischemia- reperfusion as closely as could be achievable in clinical 
settings. Extensive preclinical data indicate that neuroprotection is (a) most effective in ischemia reperfusion and (b) targeted to the penumbra.  Thus it is most rational to evaluate neuroprotection in stroke patients who meet the ESCAPE criteria for endovascular recanalization therapy
3.  
4.7 Endovascular A cute Stroke Therapy  
Endovascular treatment for AIS has now been shown to be of clinical benefit in appropriately 
selected patients  and is anticipated to  become a standard of care.  Six randomized tr ials – ESCAPE, 
EXTEND -IA, SWIFT PRIME, REVASCAT, 
MRCLEAN, THRACE - have demonstrated the 
benefit of endovascular therapy over best medical management.
3-7  The last of these, THRACE, has been 
presented only in abstr act form.   These publications cap 
a tremendous period of clinical activity after prior trials of endovascular stroke therapy had been neutral or 
negative.
18-20 
The 
trials were similar in that all the trials used CT 
angiography to identify patients with large artery proximal occlusions.  They differed in that ESCAPE, EXTEND -IA and SWIFTPRIME used multimodal CT 
imaging (multiphase CTA in ESCAPE and CTP in 
EXTEND -IA and SWIFTPRIME) to select patients. 
These latter three trials demonstrated the largest treatment effect size, presumably by excluding more patients who would have poor outcomes despite 
treatment.  
Both ESCAPE and SWIFTPRIME developed a strong focus on the  speed of treatment.  The key messages 
from the sum of these trials are as follows: 1)Patients must be selected with CTA to identify a
target lesions – a proximal artery occlusion.
2)Patients with very poor collaterals or very large core
infarction  should be  excluded because they will not
substantially benefit.   The definition of the best
imaging paradigm for patient selection continues to be debated. 
3)Treatment must be applied very quickly.  The target interval times in ESCAPE were: CT -
to-groin puncture < 60  minutes; and CT -to-reperfusion < 90 minutes.  The ESCAPE trial

NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 30 of 88
demonstrated that median times below these thresholds were possible.  However, the 90th 
percentile times were well above these thresholds3. 
4) H igh rate s of reperfusion  must be achieved rapidly and safely .
The st
rong evidence that endovascular therapy is effective in improving neurological outcome in 
patients with large vessel arterial occlusions now provides a human paradigm of the ischemia -
reperfusion model that simulates animal models of ischemia -reperfusion that are widely used in 
preclinical stroke research  and in which stroke therapies, especially neuroprotectants, have been 
evaluated .  Until recently, the potential of endovascular recanalization to improve clinical outcome 
in past human trials was  confounded by the failure of imaging selection, slow treatment paradigms 
and failure to fully reperfusion the brain.  It is likely that such trials included patients in whom the 
brain was no longer salvageable, or in whom arterial occlusion was longstanding. Based on 
knowledge from preclinical animal studies, it is likely that permanent ischemia models are much 
more resistant to treatment.  The results of the most recent endovascular trials now provide us with 
the opportunity to properly explore the concepts of neuroprotection and reperfusion injury and whether pharmacological or biological agents may allow incremental improvements in outcome for patients treated in this fashion.  The human paradigm will no longer be confounded by a failure 
of reperfusion  and the endovascular trials have successfully defined the target patient population 
with potentially salvageable brain .  The use of NA -1 will be explored  as an adjuvant agent for 
neuronal cytoprotection in the setting of AIS . 
A key benefit of this approach is that NA -1 may result in a “freezing” of the core until reperfusion 
can be achieved
15.  This concept may extend to the application of treatment at distant sites to buy 
time until reperfusion therapy can be achieved.  Further, there is evidence that cellular damage induced by ischemia continues even after reperfusion.  This, so- called reperfusion injury, may be 
attenuated by adjuvant medical therapies such as NA -1. 
4.8 Imaging as a Biomarker for P atient  Selection  
There is consensus in the stroke research community that a treatment benefit can only accrue if the treatment is given to a subject with salvageable tissue -at-risk. The theoretical construct used to 
define this tissue at risk, or “penumbra” using medical imaging comprises the difference between imaging tissue destined for infarction and tissue that is already irreversibly infarcted (the “mismatch hypothesis”). Whereas the best method for imaging “mismatch” remains controversial, in this study we are operationally defining “mismatch” using simple CT or MRI criteria that are rapidly implementable and are unambiguous. These criteria aim to enroll subject  with large 
volumes of tissue -at-risk based on the finding of a large arterial occlusion while exclude those with 
large core infarctions, as the latter are unlikely to benefit from endovascular therapies
21. 
Based on a synthesis of past studies, we have derived the following key clinical and imaging 
criteria for selecting subject  for this study: 
1)Moderate to severe ischemic stroke defined as >5 on the NIHSS.
2)No evidence of extensive infarction, defined as tissue hypodensity on NCCT scan on thebasis of Alberta Stroke Program Early  CT Scan ( ASPECTS ) scoring system, or as
extensive apparent diffusion coefficient ( ADC ) restriction/DWI lesion volume (>100cc)
on MRI.
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 31 of 88 
 3) A large arterial occlusion (carotid artery or proximal MCA) as defined by non -invasive 
imaging.  
4) Evidence of adequate pial  collateral filling.  
5) Arterial occlusion amenable to safe and fast recanalization using endovascular means or combined intravenous thrombolysis plus endovascular treatment. 
These criteria can be met using CT scanning and the data can be gathered and interpreted in <10 minutes.  Using the ASPECTS, extensive infarction can be excluded.  Using CTA detailed 
information can be gained on the location of occlusion and the burden of thrombus.  Further, the CTA (from arch to vertex) can aid the interventionist in pre -planning navigation from the aortic 
arch to the thrombus.  The pattern of collaterals is also discernible from CTA; patients with absent or very poor collaterals do not benefit from therapy, simply because it cannot be brought to bear in a timely enough fashion to prevent significant infarction. In ESCAPE
3, slightly more than half 
of patients were imaged using multi- phase CTA.  Single -phase CTA and dynamic/multiphase  CTA 
were used to select patients in the remaining cases.  Many sites had access to CTP imaging but did not use it for patient selection.   However, the pattern of collateral circulation can be assessed using 
CTP imaging.  
Thus, a fast image acquisition “good scan (small core), proximal occlusion, adequate collaterals” model of patient selection is being adopted. This group of patients has shown a large treatment effect of endovascular therapy.  This group of patients represents the near ideal “ischemia -
reperfusion” paradigm.  Thus we propose that it is the best subset of stroke patients in which to 
test the benefits of neuroprotection.  
  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 32 of 88
5 TRIAL OBJECTIVES  
5.1 Primary Objective  
The primary objective is to determine the efficacy of the neuroprotectant, NA-1, in reducing global 
disability in subjects with major AIS with a small established infarct core and with good collateral 
circulation selected for endovascular  revascularization.  
5.2 Secondary Objectives  
The secondary  objectives  are to determine the efficacy of NA -1 in: 
•Reducing functional dependence
•Improving neurological outcome
•Improving activities of daily living
•Reducing mortality rate
5.3 Tertiary Objectives  
The tertiary objectives are to determine the efficacy of NA -1 in: 
•Improving health -related quality of life.
•Decreasing infarct volume at follow -up imaging
•Improving cognitive function
5.4 Leading Safety Objectives  
The leading safety objectives are to determine the effect of administering a dose of 2.6 mg/kg (up 
to a maximum dose of 270 mg) intravenous infusion of NA -1 to subject  with acute stroke who are 
selected for endovascular revascularization on SAEs and 90-day mortality.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 33 of 88
6 TRIAL DESIGN 
This is a P hase 3 randomized, multi centre, blinded, placebo- controlled, parallel group, single -dose 
design.  Subjects harboring an acute stroke and who are selected for endovascular revascularization 
in accordance with local institutional practices and who harbor a small established infarct core and 
with good collateral circulation will be given a single, 2.6 m g/kg (up to a maximum dose of 270 
mg) intravenous dose of NA -1 or placebo as soon as they are deemed to have met the enrollment 
criteria and with the intention of start ing administration  within 30 minutes of randomization.  
A total of 1120 subjects aged 18 years and older will be enrolled into the study.  All subjects will 
be followed for 90 days (or until death if prior to 90 days).  Further details on the study procedures 
can be found in Table 2 -1: Schedule of Assessm ents.  The end of study is defined as the date that 
the last enrolled subject has completed their Day 90 visit.  
6.1 Outcomes  
6.1.1 Primary Efficacy Outcome  
The primary efficacy outcome variable for the pivotal assessment of efficacy for regulatory submission purposes is the overall proportion of subjects  experiencing a favorable functional 
outcome 90 days post-randomization, defined as 0 to 2 on the mRS. These subject s are defined to 
be responders. 
6.1.2 Secondary Efficacy Outcomes  
The key secondary efficacy outcome is the shift of one or more categories to reduced functional 
dependence analyzed across the whole distribution of scores on the mRS at Day 90 or the las t 
rating.  
Other secondary outcomes include: 
1)Proportion of subjects with good neurological outcome, as defined by a score of 0- 2 on the
NIHSS at Day 90 or the last rating.
2)Proportion of subjects with functional independence in activities of daily living, a s defined
by a score of ≥ 95 on the BI at Day 90 or the last rating.
3)A reduction in mortality rate, as defined by event rate (%) for mortality over the 90- day
study period
4)Proportion of subjects with functional independence, as defined by a score of 0- 1 on the
mRS at Day 90 or the last rating.
6.1.3 Tertiary Outcomes  
The following tertiary outcomes will be assessed descriptively:  
1)Health -related quality of life, as measured by the EQ-5D- 5L at Day 90 or the last rating.
2)Volume of stroke as measured by a) DWI and b) FLAIR at 24 Hour follow -up. If NCCT
was done instead of MRI, Volume of stroke will be derived from hypodense areas.
3)Cognitive outcomes, as measured by the 15 -item Boston Naming Test (BNT 15),
Sunnybrook Hemispat ial Neglect Procedure (SNAP) and the Montreal Cognitive
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 34 of 88
Assessment ( MoCA). 
4)The proportion of subjects experiencing a favorable functional outcome 30 days post -
randomization, defined as 0 to 2 on the mRS.
6.1.4 Safety Outcomes  of Special Interest  
The primary safety outcomes are the frequencies of SAEs and 90 -day mortality.  
6.1.4.1 Guidance on Definitions of Selected Safety Outcomes  
Symptomatic intracranial hemorrhage (ICH) defined according to the Heidelberg classification, as 
a new ICH  [intracerebral hemor rhage , SAH, intraventricular hemorrhage (IVH), subdural 
hematoma (SDH)] associated with clinical evidence of neurological worsening, in which, the 
hemorrhage is judged to be the most important cause of the neurological worsening.  Clinical 
worsening will be guided by the NIHSS score of a minimum of two or more points different from baseline.  
Major extracranial hemorrhage defined as  life-threatening, resulting in hemodynamic  compromise 
or hypovolemic shock, requiring inotropic support or other means to maintain cardiac output, requiring blood transfusion of more than two units of packed red blood cells, or associated with a fall in hemoglobin greater than or equal to 5 g/L. 
Contrast medi a-induced nephropathy will be defined as  a rise of the serum creatinine  of ≥ 0.5 
mg/dl (≥44 mmol/l) or  a ≥25% increase from baseline pre -treatment level  within 3 days after the 
endovascular procedure without an alternative etiology.  A ny creati nine measurements conducted 
as part of the protocol or standard of care in the first 3 days after the endovascular procedure in 
patients suspected by their treating physician of having a contrast nephropathy will be considered 
for this adjudication. . 
Total radiation dose will be measured in mSv and recorded directly from the CT scanner.  Dose -
length product will be recorded  directly from the CT scanner.  
Malignant MCA infarction will be defined as any large infarction with mass effect observed on 
imagin g where treatment (medical or surgical) is required for the treatment of mass effect.  
Hemicraniectomy will be defined as that surgical procedure used to decompress the swollen hemisphere.  
Vessel perforation will be defined at angiography by the operator and associated with sub -
arachnoid hemorrhage. 
Iatrogenic arterial dissection will be defined at angiography by the operator.  
Arterial access site hematoma will be assessed as a complication of arterial access puncture and 
defined by clinical examination and anatomic imaging.  
Retroperitoneal hematoma will be assessed as a complication of groin puncture and defined by imaging ( ultrasound or CTA or MR).  
Femoral neuropathy will be defined clinically and shall be considered related to the procedure if it is ipsila teral to the angiography puncture site and occurring with several weeks of the procedure.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 35 of 88
6.2 Randomization and Blinding  
Treatment will be assigned using 1:1 randomization (placebo:NA -1) central ly, using a web -based 
algorithm with treatment assignment allocate d by web -based real -time interaction with the site. 
Randomization will be f ully concealed  by having both dynamic real -time allocation based upon 
random number generation and visually identical appearing NA -1 and placebo vials.  A ll vials will 
have a unique vial number.  
In order to minimize  differences between the two treatment arms of the trial other than the  
investigational treatment, the protocol will restrict the use of multiple non -randomized intra-
arterial therapies  and stratify randomization by  (a) use of intravenous thrombolysis with alteplase 
(yes/no) and (b)  the declared first thrombectomy approach. Th e intended first thrombectomy 
approach  will be restricted to the use of either a stent retriever or clot aspiration device. The intent 
to use any other endovascular device type or intra -arterial medications as the initial thrombectomy 
approach constitutes an exclusion criterion. Additionally, if intravenous thrombolysis is planned 
for the subject, the intent to use any intravenous thrombolytic ot her than alteplase is an exclusion 
criterion.  
Thus, randomization will be stratified by declared first thrombectomy approach which will be 
dichotomized as stent retriever vs aspiration device , and by intravenous alteplase use (yes/no). 
Within each stratum,  a randomized minimization procedure will occur on 6 baseline prognostic 
variables.  Subject data required for randomization are age, sex, baseline NIHSS scores, baseline 
ASPECTs score, occlusion location and site.   The purpose of stratification is to provide increased certainty that equal or near -equal proportion 
of patients in each stratum will receive NA -1 or placebo.  
The purpose of mini mization on the variables of age, sex, baseline NIHSS score, baseline 
ASPECTS score, occlusion location (MCA or ICA), and site, which are important prognostic 
variables impacting the 90 day outcome, is to balance these variables across treatments to ensure  
a reduced chance that any observed effect size of NA -1 vs. placebo is confounded by these known 
important prognostic variables . This randomized minimization method from Zhao et al, called the 
minimal sufficie nt balance method
23, will be used to ensure that the subjects entered into the trial 
will be balanced between control and active treatment arms . Further  details of the minimization 
procedure are provided in Appendix 3 – Randomization Details . 
The time of randomization is defined as  the time randomization occurred on the central server  and 
this time is considered time zero for the study.  Study drug will be infused immediately afte r 
randomization with the intention of starting administration within 30 minutes of randomization . 
Study drug should be administered within 60 minutes of the NCCT.  
All subject s that are randomized will be accounted for in the trial  database a nd followed r igorously 
for the primary and key secondary outcomes to minimi ze issues of imputation/missing data. The 
randomization number and time  will be automatically printed from the randomization website and 
it will be transmitted to the central database to create the case in the electronic case report form ( e-
CRF ).  The randomization date, time, the two stratification variables , tPA use, first declared device 
and the six key randomization variables, age, sex, baseline NIHSS, baseline ASPECTS, occlusion 
location  and site will not be editable once the subject is randomized.  Thus, once a subject is entered 
into the randomization website, that subject’s e-CRF will be auto -created and ready for data entry.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 36 of 88
The automated system will inform site staff when  re-stocking of the refrigerator is required and 
will specify the vial numbers to be restocked.  This will ensure that a blinded investigator cannot 
match a vial that was just given to a subject  to a single re -stocked vial and adds to the assurance 
of the study blind. Re-stocking will take place within one business day per the local participating 
site’s working practice.  
All subjects, investigators, their clinical staff, the clinical coordinating centre, the data 
management group, and the sponsor staff and delegates will be blinded to the randomization codes. The local laboratories will also be blinded.  
The IDMC reports and analyses for Closed Sessions will be organized by treatment arm 
(“unblinded”). In order to ensure confidentiality and minimize bias, the information will be 
provided to the IDMC by a group that is independent of the sponsor and blinded project team implementing the trial. A firewall will be maintained between the IDMC (unblinded) and the project staff (blinded).
 
The person responsible for the study drug labelling  will be unblinded, as will the independent 
statistical group preparing the reports for the IDMC.   The person responsible for the data 
management group, who manages the programming of the randomization system  will be 
unblinded. This  individual will be the contact person in the event that unblinding is necessary 
(Section 6.3). This individual will not participate in data management and will only communicate 
unblinded data as set out below when contacted by the medical monitor.  
6.3 Procedure for Breaking the Randomization Code 
To maintain the overall quality and legitimacy of the clinical trial, code breaks should occur only 
in exceptional circumstances when knowledge of the actual treatment is absolutely essential for further management of the patient  to ensure their  safety and well-being .  The Investigator is 
requested  to maintain the blind as far as possible. If at all possible, the actual treatment allocation 
should not be disclosed to the subject and/or other site personnel unless, in the judgement of the 
investig ator, this information is required for the subject ’s safety. The actual treatment allocation 
must not be disclosed to study personnel on site not involved in the subject ’s medical care, to  
monitors or the sponsor.  The investigators have the final decision and unilateral right for  
unblinding. 
In case of emergency, a rapid unblinding procedure is available to investigators.  If the investigator 
decides that the treatment code needs to be broken in the interest of subject safety, the investigator 
will have direct access to the ESCAPE -NA1 CRU centre  to request unblinding of the specific 
subject. The CRU will respond in writing to the investigator only with the unblinded patient 
treatment allocation.  
Only the investigator requesting the unblinding will receive the unblinding information. The investigator will promptly inform the Sponsor when an request to unblind is made and the 
circumstances involved.  Any case that is unblinded in this way will be documented in a blinded manner in central files.   
In order to fulfill expedited regulatory reporting requirements, the Sponsor may be required to unblind the subject if the SAE meets the criteria for reporting to health a uthorities .  The Medical 
Moni tor or Drug Safety Manager will initiate the request that the subject’s treatment group be 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 37 of 88
unblinded.  In this case, the code will be broken only for the subject(s) in question. The information 
resulting from code -breaking (i.e., the subject’s dose assignment) will not be communicated to 
either the Investigator or any other clinical team member of the Sponsor.  
Otherwise, randomization data will be kept strictly confidential, accessible only to authorized 
persons, until the time of unblinding after data lock at the  time of interim analysis and at end of 
the study. 
6.4 Treatment  
6.4.1 Dosage Form, Accountability and Labeling 
NA-1 was formulated at 20 mg/ml under current Good Manufacturing Practices by The University 
of Iowa College of Pharmacy in 50 mM sodium phosphate buffer with 0.45% sodium chloride 
(NaCl) , potential hydrogen ( pH) 7.0.  This formulation was dispensed aseptically into 30 mL vi als 
with snap cap lids (13.5 mL) intended for a single-dose intravenous injection of NA-1.  
Placebo consists of the same buffer used for NA -1 with slightly high er NaCl  content to adjust for 
equivalence of osmolality between drug product and placebo.  It is supplied in identical vials 
containing 13.5 mL of 50 mM sodium phosphate pH 7.0 (0.55% NaCl). 
Formulated NA -1 and placebo will be delivered in sterile, single -use individually labeled  vials 
(serum vials)  each with a unique five-digit identification number each with a unique five-digit 
identification number , and  will be stored at the clinical site at 2 to 8°C in a secure l ocation with 
restricted access.  
Records will be made of the receipt and dispensing of the study drugs supplied.  Documentation 
for each study drug will include, but may not be limited to, the following information: 
1)Receipt date
2) Description of drug package, and drug product
3)Lot/Batch/Five -digit Code
4) Expiry and/or Manufacturing and/or retest date5) Dispensing information.
Drug vials will be labeled  in accordance with applicable regulatory requirements.  
6.4.2 Disposition of Study Drug Supplies  
After study drug preparation, any remaining material in the vial will be labeled  as “used,” and the 
volume removed will be recorded on the label or source document (value in mL).  Vials labeled  as 
“used” will be retained in a separate storage container than the unused vials, and will be shipped 
to a location specified by the sponsor, upon the sponsor’s request. Used vials will be disposed of 
on site, once the CRA has completed the study drug monitoring.  Unused vials will be  returned to 
the sponsor  or disposed of on site  after they have been monitored by the sponsor or sponsor’s 
representative. Destruction of unused vials on site will be documented and conducted in  
accordance with the site’s procedures.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 38 of 88
6.5 Study Drug Monitoring  
At each applicable monitoring visit, the monitor will verify that:  
•Study drug vials  are appropriately stored  in the refrigerator  at 2 to 8 °C in a secure location ,
and that they have the correct expiry date
•CT area refrigerators are being re- stocked in a timely fashion
•Dose volume, start and stop time, and subject weight are recorded after each randomization
•Any expired, lost, damaged or out -of-specification medication has been properly reported
and documented, and follow-up has been conducted
6.6 Case Report Forms  
All source documentation will be reviewed for compliance with GCP.  Case report forms (CRF) 
for the study are electronic.  
6.7 Process, Timing and Quality Assurance Metrics  
To ensure that the process and quality of key activities related to randomization, drug dosing and 
thrombectomy procedures and patient follow up are in place, process (including timing) and quality assurance metrics will be followed on an ongoing basis throughout the study by reviewing data collected in the CRF.  The metrics that will be followed include: 
1)Time from randomization to start of study drug administration (<30 min)
2) Time of Drug infusion start to drug infusion completion (10 ± 1 minutes)
3)Time of stroke onset to time of study drug infusion start
4)Time of stroke onset to reperfusion
5)Time of start of study drug administration to reperfusion
6)NCCT-to-study drug initiation time  (<60 min)
7)NCCT-to-groin puncture time (“picture- to-puncture”) (<60 min)
8)NCCT-to-recanalization time (“picture -to-reperfusion”) (<90 min)
9)Rate of aspiration  pneumonia
10)Rate of use of general anesthesia
11) Rate of symptomatic deep venous thrombosis/pulmonary embolism12) Proportion of subject with any SAE per site13)Fidelity of primary thrombectomy device intended for use v ersus  primary thrombectomy
device actually used .
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 39 of 88
7 SELECTION AND WITHDRAWAL OF SUBJECTS  
7.1 Study Enrolment Process  
Subjects  will be identified using usual standard of care screening methods at the acute stroke 
hospital.  This will include screening by neurolo gy residents, fellows, nurse pr actitioners, 
physician assistants or faculty physicians.   
Sites will only be selected to participate in the study if they have established  mechanisms for 
screening this population of subject .  This includes standard of care use of NCCT and  CTA. 
All subject s will undergo an acute clinical assessment, blood laboratory assessment and baseline 
brain imaging . For the standardization of the imaging criteria for patient selection across sites, all 
sites will perform a NCCT brain and CTA to determine patient eligibility.  The NCCT head will 
be assessed using ASPECTS (Alberta Stroke Program Early CT Score) prior to randomization. 
Patients with an ASPECT S score of 5 or greater may be included in the study.  ASPECTS is a 
reliable and reproducible assessment tool with l ow inter - and intra -observer variability22 and is 
used to standardize the imaging criteria used for patient selection.  The CTA will be also assessed for collateral status using a collaterals scoring system similar to that used for patient selection in the ESCAPE trial.  Instructions for the determination of the ASPECTS score and collaterals 
scoring on CTA are provided in Appendix 2: Derivation of ASPECTS on NCCT and Collaterals 
Scoring on CTA  and additional details can be found at  www.aspectsinstroke.com .  
From  the perspective of imaging to recanalization and other interval times, the first slice of the 
baseline NCCT is when the timing begins.   
If CTP is done routinely at the site, NCCT and CTA must still be used to determine inclusion 
criteria .  It is mandated that a CTP cannot be performed before the CTA. 
In order to track the potential for enrolment, each enrolling site will provide the total number of patients admitted to that site with the diagnosis of AIS . Individual patient screening logs will not 
be required. 
If the subject remains eligible after completion of routine screening, the patient will be consented 
(as required ) and enrolled into the study.  A patient who consents but is not randomized will be 
considered a screen failure.  A subject  is considered randomized  the moment the randomization 
process is completed on -line.  This is time “0” for the study.  Subjects who are randomized but do 
not receive study drug will still be followed through the 90-day study period.  
7.2 Inclusion Criteria  
1)Acute ischemic stroke ( AIS) for immediate endovascular treatment .
2)Age 18 or greater .
3)Onset (last -seen-well) time to randomization time within 12 hours.
4) Disabling stroke defined as a baseline NIHSS > 5 at the time of randomization.
5)Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily
living with  modified Barthel Index ( BI) > 90 (95 or 100).  Patient must be living in their own
home, apartment or seniors lodge where no nursing care is required.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 40 of 88
6)Confirmed symptomatic intracranial  occlusion, based on multiphase or dynamic CTA, at one
or more of the following locations: Intracranial, carotid T/L, M1 MCA.  Anterior temporal
artery is not considered an M2.  Functionally, when defining the M1 MCA, the bulk of the
MCA territory must be ischemic .
7)Non-contrast computed tomography ( NCCT) and CTA * for trial eligibility performed or
repeated at ESCAPE -NA1  stroke centre with endovascular suite on- site.
8)Endovascular treatment  with declared first endovascular approach as eit her stent retriever or
clot aspiration device, and intended to be initiated ( arterial access ) within 60 minutes of
baseline/qualifying  NCCT wi th target baseline /qualifying  NCCT to first recanalization of 90
minutes .  Study drug intended to be administered wi thin 60 minutes of the baseline/ qualifying
NCCT.
9)Signed informed consent from subject or legally authorized representative  or, if required to
enable inclusion by applicable national laws and regulations and the applicable independent
review boards/Ethics Committee requirements for obtaining consent, from the investigatorafter consultation with an independent physician who is not otherwise participating in the trial.
*As per the List of Abbreviations ( Section 1.2), all references to CTA indicate a multiphase or
dynamic CTA.
7.3 Excl
usion Criteria  
1)Evidence of a large core of established infarction  defined as ASPECTS 0 -4.
2) Evidence of absence of collateral circulation on CTA (Collateral score of 0 or 1).3)Intent to use any endovascular device other than a stent retriever or clot aspiration device or
intra-arterial medications as the initial thrombectomy approach.
4)Intent to use any intravenous thrombolytic other than alteplase if intravenous thrombolysis isplanned.
5)No femoral pulses, very difficult endovascular access or extreme tortuosity of the great vessels
that is predicted to result in an inability to timely deliver endovascular therapy.  Direct common
carotid or radial/brachial/axillary access is permissible.
6) Estimated or known weight > 120 kg or < 45 kg.
7)Pregnancy; if a woman is of childbearing pot ential a urine or serum β-hCG test is positive , or
breastfeeding .
8)Severe contrast allergy or absolute contraindication to iodinated contrast  preventing
endovascular intervention including any contraindications listed in the prescribing information
approved by local authorities (e.g., patients with decompensated heart failure as a
contraindication for the use of VISIPAQUE
TM 270 in Germany).
9)Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is
chronic or there is suspected intracranial dissection such that there is a predicted lack of success
with endovascular intervention.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 41 of 88
10) Prior enrolment in the ESCAPE -NA1  trial or prior receipt of NA -1 for any reason.
11) Severe known renal impairment defined as requirin g dialysis (hemo - or peritoneal) or if known
creatinine clearance < 29 mL/min.
12) Patient has a severe or fatal comorbid illness that will prevent improvement or follow -up.
13)Patient cannot complete follow -up treatment due to co -morbid non- fatal illness or they are a
visitor to the city or any other known reason that follow -up would be impossible (e.g.
incarcerated in a federal prison).
14)Participation in another clinical trial investigating a drug, medical device, or a medical
procedure in the 30 days preceding study inclusion.
This population is expected to consist of subject  very similar to those treated in the ESCAPE trial.3 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 42 of 88 
 8 TREATMENT OF SUBJECTS  
8.1 Study Interventions 
Patients who are deemed to be candidates for endovascular intervention i n accordance with the 
inclusion/ exclusion criteria will be ra ndomized to receive NA -1 or placebo .  
8.1.1 Administration of Study Drug  
8.1.1.1 Timing of Dose Administration  
The enrolling specialist will determine if the patient is a candidate for endovascular reperfusion 
based in the study i nclusion/exclusion, consent has been obtained and randomization allocation 
has occurred .   
At the time that a patient is deemed to be eligible for endovascular recanalization, the research coordinator (or delegate) will log into the central randomization w ebsite, enter key variables, and 
the website will inform which of the vials in the refrigerator should be used for that subject based on the current balance in the trial assignment of the baseline characteristics of all subjects randomized to date.  The re search coordinator (or delegate) will then select that single vial of study 
drug from the refrigerator and prepare it for administration.  
Dose timing shall start at the time of drip onset.   Study drug is intended to be administered within 
60 minutes of the NCCT and within 30 minutes of randomization. The time of dosing onset and the time at which the endovascular angiographic procedure began (insertion of an angiogram sheath into the femoral (or other relevant) arter y at the start of the procedure) will be recorded on 
the CRF.  
8.1.1.2 Dose Administration 
Dosing will be carried out by, or under the supervision of, the trial physician  who is supervising 
the care of the subject for the planned or ongoing endovascular reperfusion procedure.  
A syringe for each individual subject dosing will be prepared by calculating the volume to draw from the vial as follows: for subjects weighing less than 105 kg:  (2.6 mg/kg x subject weight in 
kg)/(20 mg/ml).  This will determine the number of  mL to pull up into the syringe.  For subject 
weighing 105-120 kg the full volume of one vial (13.5mL, equivalent to 270 mg of NA -1) will 
be used.  
The syringe containing study drug will be injected into the intravenous port of a 50 or 100 mL 
drip bag of 0.9% normal saline that has been labeled with the randomization number and subject’s age.  The bag will be mixed by squeezing and inverting the bag s everal times.  After 
dilution into the drip bag, the drug is stable for up to 5 hours, however it should be infused into the subject as soon as practical with a target randomization to treatment time of 30 minutes or less.   
An appropriate sized syringe must be used, such that this volume is between 20% and 100% of the delineated markers on the syringe.   Once a volume of drug has been drawn into the syringe, the vial will be marked as “used” and placed into a separate vial storage area.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 43 of 88
Dosing will be performed by administering the contents of the bag of study drug to the subject 
through an intravenous catheter inserted into a vein in the upper or lower extremity and using a 
standard infusion pump. Dosing will be carried out evenly over the  course of 10 ± 1 minutes while 
the intravenous bag contents are administered to the subject. The entire volume (treatment dose) 
of the intravenous mini- bag must be administered.   
After the dose administration, a minimum of 10 mL of saline will be adminis tered using the 
infusion pump, to flush any remaining medication left within the intravenous tubing.  This method 
of dose administration is identical to that previously conducted in the Phase 2 ENACT trial11. In 
the event that a subject  is concomitantly receiving alteplase therapy, dose administration of NA-1 
will be conducted through a separate intravenous catheter inserted into an extremity not containing 
the alteplase  line. If alteplase therap y has been completed, the same intravenous catheter may be 
used after it has been flushed with saline . 
8.2 Interventions  
8.2.1 Endovascular Intervention 
The neuro- interventionalist will pre -declare, prior to randomizati on, their preferred first 
endovascular device type to be used in the procedure, defined as either a ‘stent retriever 
thrombectomy’ or ‘aspiration thrombectomy ’. Any currently available and approved/cleared  
device may be used for this purpose.  T he neuro- interventionist should adhere to using this declar ed 
device when making their first approach. If the first approach fails, the neuro -interventionalist may 
use their best medical judgment to complete the procedure  in the patient’s best interest. The use of 
a balloon guide catheter is recommended  with the stent retriever approach . 
Any use of an intra-arterial  medication such as a thrombolytic agent (eg. alteplase) or antiplatelet 
agent  is known to be uncommon and will be recorded in the concomitant medications list.  
Permanent  stents should not be left in the intracranial circulation or in the internal carotid artery , 
except under exceptional circumstances dictated by the needs of acute patient care.  
Guid ance for recommended approaches to endovascul ar revascularization are provided in 
Appendix 1 – Guidance on Imaging Selection and Endovascular Treatment . 
8.2.1.1 Acute Carotid Artery Stenting  
It is recommended that c arotid  artery stenting should not be undertaken acutely in order to avoid 
the need for dual antiplatelet agents.  It is strongly recommended  that neuro -interventionists tackle 
the intracranial occlusion primarily and only then consider the extracranial carotid artery.  In some 
circumstances,  carotid angioplasty , without stenting may be required with a planned return to the 
neuro- intervention suite 2 -3 days later for definitive carotid management with stenting.  It is 
recognized that caroti d artery stenting may still be required in some circumstances.  The use of 
carotid artery intervention (angioplasty with or without stenting) will be monitored and specific 
data collected .  
8.3 Guidelines -based Medical/Stroke Unit Care  
All a cute stroke subject s should receive the best standard of care according to national guidelines. 
The model will be the Canadian best practices guidelines for acute stroke care.  These are very 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 44 of 88
similar to the guidelines of the American Stroke Association and the European Stroke 
Organization.  All subjects are expected to be admitted to hospital as part of routine standard of care.  
It is expected that all subjects will undergo a routine work -up for the mechanism of their stroke 
and be treated appropriately and definitively.   This is critically important because subjects who 
have an excellent early recovery are at the highest risk of early recurrent stroke.
24  We wish to 
prevent recurrent stroke from confounding the 30- day and 90- day clinical outcome such that 
subject  who are well at discharge remain that way for the duration of the  90-day follow -up period.  
We expect the following preventive care.  Relevant subject  with atrial fibrillation should be anti-
coagulated.  Patients with symptomatic carotid artery stenosis should undergo carotid revascularizati on early and definitely within two weeks of stroke onset.
25  Risk factors, including 
hypertension, elevated cholesterol, diabetes mellitus, tobacco smoking, should be treated appropriately and aggressively according to current standards of care. 
We expect subject s to receive adequate hydration to prevent renal complications.  Patients will 
receive intravenous radio -contrast media for CTA  for endovascular intervention.  While these  
medication s are generally extremely  safe in stroke patients,
26 simple hydration can prevent renal 
complications, particularly among patients with baseline borderline renal function and among 
those with diabetes mellitus.  Further, patients with ischemic stroke are generally  slightly 
hypovolemic at baseline.  We recommend use of intravenous normal saline (0.9% saline) infusion 
at 1.5 – 2.0 cc/kg/h until the subject is eating and drinking safely and well.   Therefore, for the 
typical subject this will mean intravenous normal s aline  at 75 -125 cc/h overnight only.  We do not 
recommend the use of bicarbonate solutions or N -acetyl -cysteine solutions for renal protection.27,28  
In general, the risk of nephrotoxicity from modern non- ionic, iso-osmolar radiocontrast media is 
extremely low.  
For subject s that are disabled from their stroke and require a longer in -patient stay and/or 
rehabilitation, it is expected that they will receive standard stroke unit care to prevent complications.  These include: 
•Deep vein thrombosis ( DVT ) prophylaxis for subject  who are bed -bound or primarily
bed-bound
•Swallowing assessments and prevention of aspiration pneumonia
•Early mobilization and physiotherapy to prevent skin breakdown, pneumonia,DVT/pulmonary embolism beginning 24 hours after randomization
•Early diagnosis and treatment of fever
All subject s are expected to receive expert stroke unit care and then rehabilitation according to 
their clinical need.  
In brief, it is expected that: 
1)Patients who are appropriate candidates for intravenous thrombolytic therapy within 4.5
hours of defined stroke onset to get rapidly administered intravenous alteplase  therapy.
2)All subject s should be managed urgently with attention to physiology.  Airway, breathing
and circulation (ABC) first.  Fluids – usually normal saline - should be administered,  as
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 45 of 88
most patients are slightly hypovolemic.  BP should not be aggressively treated other than 
to guidelines to allow thrombolytic therapy.  
3)All subject s should be managed on a stroke unit which should include early mobilization,
early rehabilitation, DVT prophylaxis, swallowing assessment and prevention of aspiration
pneumonia, nasogastric ( NG) feeding as appropriate and delayed (up to four  weeks)
placement of percutaneous endoscopic gastrostomy ( PEG ) tubes in the uncommon instance
that these are needed.
4)All subject s should receive ASA therapy (minimally) within the first 48 ho urs of stroke but
after a day plus one brain image showing no evidence of major hemorrhage.
5) Patients should not receive intravenous unfractionated heparin.6)All subject s should be thoroughly investigated to sort out the mechanism of stroke and
appropriate stroke prevention strategies implemented.  There is little use in working veryhard on a technical and aggressive approach to acute stroke if it is to be undone on day +10
with a recurrent embolus because a subject  has not been effectively treated for a
preventable cause of stroke.
7)All subject s should have relevant and appropriate stroke rehabilitation therapy  including
physical, occupational and speech therapy.
In summary, it is  expected  that all subject  should have excellent, guideline based stroke care 
through the full 90 days.  
8.4 Speed of Intervention  
A key principle of the neuroprotective and endovascular intervention is that it must be both fast 
and safe.  The target NCCT to revascularization time is  the 90
th percentile < 90 minutes and median 
at 75 minutes  or less .  Similarly, an interim measure will be the NCCT to groin puncture time at 
90th percentile of <60 minutes and median at <45 minutes.  This will be measured from the time 
of the first slice of the baseline/qualifying  NCCT head done at the ESCAPE -NA1  centre.   The 
target complication rate is less than 1%.   The quality of intervention will be ensured by hand-
selection of sites and only be approved by the executive committee after a site visit.  All sites  will 
be selected from the ESCAPE trialists.  New sites must submit evidence within the two  years prior 
to commencement of the trial that they can meet the 90-minute  target of CT -to-recanalization time .  
For sites that participated in the ESCAPE trial, their trial data will constitute p roof of capability of 
treatment . A principle of the evaluation of neuroprotection by NA -1 is that it should be 
implementable without significantly delaying the subject ’s access  to reperfusion.  
A key and critical component of the trial will be an ongoing quality assurance program to ensure 
that sites can meet these targets for endovascular intervention.  Training will be undertaken at the sites and continued on a quarterly basis.  Monitoring of interval times will be collated and provided 
to sites on a quarterly basis so that regular feedback might induce appropriately fast treatment processes.  Sites that fail to meet these objectives in the trial will be dropped from the trial.  
The sites will be assisted to achieve these targets.  
8.5 Consent Process  
Signed informed consent will be obtained prior to any protocol- specific procedures  from the 
subject or legally authorized representative or,  if required to enable inclusion by applicable 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 46 of 88
national laws and regulations and the applicable independent review boards/Ethics Committee 
requirements for obtaining consent, from the investigator after consultation with an independent physician who is not otherwise participating in the trial. 
If the original process involved anyone other than the subject  , and if required by local standards , 
consent will be sought for the remaining procedures from the subject  once they are deemed to have 
regained capacity . 
8.6 Baseline Clinical and Laboratory Evaluations 
At Baseline, all subject s will undergo a routine neurological and clinical assessment  (including 
history, examination and vital signs) , the NIHSS and pre-stroke BI.   
Emergency blood work will be drawn including : CBC  (hemoglobin, platelets and hematocrit) , 
electrolytes  (sodium, potassium, chloride) , INR, aPTT, serum creatinine and serum glucose.  The 
study will use and collect local laboratory results and will not  use a central lab.   The results of this 
blood work are not required prior to randomization. 
If the subject  is female and is of childbearing potential a pregnancy test (urine point -of-care 
pregnancy test) must be completed and the result must be negative; this is the only mandatory 
laboratory test prior to randomization. Other laboratory or point -of-care testing may be performed 
at the discretion of the attending physicians and team.   
An ECG should be completed at baseline. If  the treating physician deems that a baseline ECG 
impedes the patient’s access to timely care, the ECG must be performed  within 6  hours of 
randomization. All prior medications taken within three days of treatment initiation will be recorded on the e -CRF. 
8.7 Immunogenicity  Substudy  
Plasma samples for immunogenicity analysis will be collected at Day 1 and Day 30 from up to 
250 subjects  enrolled at a subset of sites  in Canada and the US. 
8.7.1 Immunogenicity Sample Collection  
At Day 1 (24 hours post dose – a time when no significant quantities of NA-1 remain in the 
blood) and Day 30 a 5 mL sample of blood will be collected in tubes provided by the 
Sponsor.  Sample collection method should be the least invasive to the subject and may be combined with routine blood sampling.  
The samples will be handled per guidelines/instructions provided by the sponsor.  These tubes 
are labeled with adhesive labels that identify the study code, site number, the subject’s number, and the sample Day.   A minimum of 1.0 mL of plasma will be transferred into each cryovial.   
The date and time for  each step (blood draw, storage, centrifugation, aliquoting, and freezing) 
and the number of aliquots obtained must be documented in the source document. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 47 of 88
8.7.2 Immunogenicity Sample Storage and Shipment  
During storage, plasma tubes are to be kept in a freezer at  -10°C or colder. The temperature will 
be monitored and documented for the duration of any sample storage. 
Plasma will periodically be shipped frozen to the sponsor.  Further shipping instructions will be 
provided by the Sponsor. 
8.8 Pha
rmacokinetics Substudy  
In order to assess Pharmacokinetics in the patient population, PK samples  will be collected at 
baseline and at multiple time points after the complete dose was administered  from up to 100 
subjects enrolled at a subset of sites in Canada and the US .  
8.8.1 PK Sample Collection  
A total of six 2 mL blood samples for PK assessment will be drawn during the Baseline Visit.  
Time (T) =0 being the initiation of dosing of study drug or placebo.  Samples will be drawn at the 
following timepoints: 
•Sample  1: post randomization & prior to start of study drug administration  (Time=0 min)
•Sample 2: 10 minutes from start of study drug administration (Time  = 10 min )
•Sample 3: 20 minutes from start of study drug administration (Time = 20 min)
•Sample 4: 30 minutes from start of study drug administration (Time = 30 min)
•Sample 5:  60 minutes from start of study drug administration (Time = 60 min)
•Sample 6: 120 minutes from start of study drug administration (Time = 120 min)
At each timepoint a 2 mL sample of blood will be collected in tubes provided by the 
Sponsor.  Sample collection method should be the least invasive to the subject and may be 
combined with routine blood sampling.  
The samples will be handled per guidelines/instructions provided by the sponsor.  These tubes 
are labeled with adhesive labels that identify the study code, site number, the subject’s number, 
and the sample date and time.  A minimum of 1.0 mL of plasma will be transferred into each 
cryovial .   
The date and time for eac h step (blood draw, storage, centrifugation, aliquoting, and freezing) 
and the number of aliquots obtained must be documented in the source document. 
8.8.2 PK Sample Storage and Shipment  
During storage, PK t ubes will be kept in a freezer at -10°C or colder. The temperature will be 
monitored and documented for the duration of any sample storage.  PK samples will be stored in 
a separate cryobox from immunogenicity samples.  All samples taken from the same subject should be stored in the same cryobox. 
PK samples will be periodically  shipped frozen to the Sponsor. Further shipping instructions will 
be provided by the Sponsor prior to study start up. 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 48 of 88 
 8.9 Brain and Neurovascular Imaging 
All subject s will initially undergo rapid NCCT and CTA imaging. Routine NCCT and CTA 
imaging guidance and minimal acceptable criteria for image quality  are provided in Appendix 2: 
Derivation of ASPECTS on NCCT and Collaterals Scoring on CTA .  Sites  that did not participate 
in the ESCAPE trial will submit sample images  to the core lab for quality assessment . 
The use of a dynamic  CTA  or multiphase  CTA  data acquisition protocol is mandatory for 
ESCAPE -NA1 . This is detailed in Appendix 2: Derivation of ASPECTS score on NCCT and 
Collaterals Scoring on CTA .  
Baseline NCCT and CTA  may be completed at a hospital affiliated with the ESCAPE -NA1 stroke 
centre, only if the baseline NCCT to drug delivery time < 60 minutes and the appropriate NCCT and multiphase/dynamic CTA are completed at the affiliated hospital provided that the imaging 
studies are available in the same medical imaging network .   
Imaging at follow -up (24h) which will be used to assess infarct volumes, will be conducted using 
MR. 
Thus, imaging and imaging assessments will be fully standardized for all assessments.  
For all interval times assessed from imaging, the time zero will be the first slice of the NC CT scan.  
The purpose of this approach is  to include imaging time and post- processing time in to any time 
metric.  
8.10 Study Drug Administration 
Dosing will begin as so on as the enrolling specialist has indicated that the subject  is a candidate 
for endovascular reperfusion based in the study inclusion/exclusion, consent has been obtained and randomization allocation has occurred.  See Section 8.1 for additional details.  
8.11 Evaluations Following Randomization 
Vital signs will be completed  pre- and post -dose and at 24 and 48 H ours, and Day 5 .  An ECG will 
be completed at 24 ± 12 Hours.  Blood tests will be conducted at 24 ± 12 Hours including : CBC  
(hemoglobin, platelets and hematocrit) , electrolytes  (sodium, potassium, chloride) , INR, aPTT,  
serum creatinine  and serum glucose. 
All subjects will undergo a follow -up brain MRI [ including a minimum of axial DWI , gradient -
echo (GRE) , FLAIR ] at 24  ± 12   Hours from the time of randomization.   The 24 -hour MR is 
considered a standard of care imaging procedure; if MR is  unavailable, then NC CT is allowed.  
All s ubjects will have a mRS scale scores evaluated at Day 5 or discharge, Day 30, and Day 90.  
Additionally, a pre -morbid (baseline) mRS will be collected and recorded on the 24h CRF page .  
All subjects will also undergo a NIHSS  assessment at 2 Hours (end of the angiogram procedure),  
24 and 48 Hours, and Day 5 or discharge, 30, and 90.  The BI will be completed at Day 30 and 90 
days. The EQ -5D-5L will be completed at  Day 30 and 90 days. 
Mortality and discharge disposition will be assessed at Day 5 or discharge.  Mortality will also be 
assessed at Day 30 and 90 . Then BNT, SNAP and MoCA will be conducted at Day 90. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 49 of 88
SAEs will be collected through to Day 90.  AEs and concomitant medications will be collected to 
Day 30 .   All time windows are calculated from the time of randomization (time ‘0’).  
8.12 Imaging 
The baseline NCCT and CTA  and all brain  imaging conducted within the first 48 hours thereafter 
will be rendered anonymous and sent to the ESCAPE -NA-1 core lab (Calgary) for central 
adjudication.  The 24 hour MR (and where MR is unavailable, CT)  will be used to assess 24 Hour 
infarct volume, an exploratory tertiary outcome . Other brain imaging will be sent only if requested 
by the adjudication committee . 
The core  imaging lab  staff will review all imaging for the acute stroke intervention period  as per 
an Imaging Adjudication Charter in order to ensure adherence to the imaging guidelines and enrollment criteria, to determine reperfusion rates and quality  of the intervention, and safety. 
Infarct volume determinations  (an exploratory outcome) will not be conducted until after database 
lock.  
8.13 Criteria for Discontinuation from the Study  
Participation in this clinical study may be discontinued for any of the fo llowing reasons: 
•Administrative reasons (uncooperative, noncompliant, etc.)
•Subject’s decision not to participate any further
•If it is in the subject’s best interest, per the qualified/principal or sub -investigator
If the subject or  legally authorized representative ( LAR ) withdraws consent, subject data will be 
included in the analysis up to the date of the consent withdrawal and this withdrawal of consent 
will be documented in the e- CRF.  
If the LAR has originally provided consent and the subject subsequently declines consent, this will be deemed to be a withdrawal of consent. The investigator and sponsor would continue to have access to data that have already been collected.  
A subject may not withdraw use of his or her data that have already  been collected, this is in 
alignment with the FDA guidance document FDA 21 CFR UCM126489, Data Retention When Subjects Withdraw from FDA -Regulated Clinical Trials
29 which states: “FDA recognizes that a 
subject may withdraw from a study; however, the withdrawal does not extend to the data already obtained during the time the subject was enrolled. FDA’s longstanding policy has been that all data collected up to the point of withdrawal must be maintained in the database and included in 
subsequent analyses, as appropriate”. 
Otherwise, all randomized subjects will continue to be followed according to protocol 
requirements and follow-up data will be included in the analysis.  Criteria for removal of subjects will be recorded and reported.  
In the event a subject is lost -to-follow up, all efforts made by the research coordinator to bring the 
subject in for a clinic visit for follow -up and this process will be documented. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 50 of 88
9 ASSESSMENT OF EFFICACY  
For the assessment scales listed below, sites and local investigators will be responsible for 
obtaining certification prior to conducting any assessments.  
9.1 The Modified Rankin Scale  
The primary endpoint used in this trial will be global disability, as measured by the mRS, at Day 
90. The mRS is a valid and reliable clinician -reported measure of global disability that has been
widely applied for evaluating recovery from stroke. It is a scale used to measure functio nal
recovery (the degree of disability or dependence in daily activities) of people who have suffered a
stroke30,31. mRS scores range from 0 to 6, with 0 indicating no residual symptoms; 5 indicating
bedbound, requiring constant care; and 6 indicating death.
The mRS will be obtained at Day 5 (or discharge), Day 30 and 90.  Premorbid mRS status will 
also be obtained retrospectively  and reported on the 24h CRF page .  The mRS will only be scored  
by those trained and certified in the use of this scale.    
9.2 The National Institutes of Health Stroke Scale  
The NIHSS is a standardized neurological examination score that is  a valid and reliable measure 
of disability and recovery after acute stroke32.  Scores range from 0 to 42, with higher scores 
indicating increasing severity. The scale includes measures of level of consciousness, extra ocular 
movements, motor and sensory tests, coordination, language and speech evaluations.  The NIHSS will be administered at Baseline, Post -EVT  (2 Hours), at  24 and 48 Hours, Day 5 or discharge, 30  
and 90. The NIHSS will only be scored  by those trained and certified in the use of this scale.  
9.3 Barthel Index  
The BI is an index of functional independence
33 that is a valid measure of activities of daily living 
when employed in stroke trials34.  Modified BI scores range from 0 to 100, with higher scores 
indicating greater independence in activities of daily living and mobility. The BI  will be scored at  
Baseline (pre-morbid) , on Day 30 and 90 by those trained in the use of this scale.  Note that the 
original Barthel Index was a scale from 0 -20.  The modified Barthel index simply multiplies the 
original scale by 5.  
9.4 Mortality Rate  
Mortality rates are defined as the number of deaths observed divided by the number of subject  
observed over the 90-day study period. 
9.5 EQ-5D-5L 
The EQ -5D-5L is a generic instrument for describing and valuing health. It is based on a 
descriptive system that defines health in terms of five dimensions: Mobility, Self -Care, Usual 
Activities, Pain/Discomfort, and Anxiety/Depression35. Each dimension has five response 
categories corresponding to: no problems, slight, moderate, severe and extreme problems36. The 
instrument is desig ned for self -completion, and respondents also rate their overall health on the 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 51 of 88
day of the interview on a 0–100 hash- marked, vertical visual analogue scale (EQ -VAS). The EQ-
5D-5L will be administered on Day 30 and 90 by those trained in the use of this scal e. 
9.6 Volume of Strokes  
After database lock, t he total volume of new a) DWI and b) FLAIR lesions in NA -1 versus placebo 
control subjects will be calculated  from the 24- hour imaging . Where MR is not available, infarct 
volumes will be determined from the 24-hour CT scan. The plan for combining CT and MRI data 
will be detailed in the imaging adjudication charter.   
9.7 Cognitive Outcomes  
The BNT 15 is a widely used  neuropsychological assessment tool  to measure confrontational word 
retrieval in individuals with  aphasia or other  language disturbance caused by various neurological 
disorders.37 
The SNAP is a short bedside battery for visuoconstructive hemispatial neglect shown to be a highly reliable and valid instruments with good internal consistency in stroke subject .
38 
The MoCA  (www.mocatest.org) has been found to be a feasible global cognitive screening tool in 
stroke trials39. It has been found to be sensitive in detecting post -stroke cognitive impairment; raw 
scores using the published cut -off score of 26 showed good sensitivity but moderate specificity. 
Montreal Cognitive Assessment scores adjusted for age and education provide both good sensitivity and very good specificity.
40  
The BN T15 (short form)41, SNAP and MoCA will be administered at Day 90 by those trained in 
the use of these scales.  Assessments will only be conducted if the tool/scale is ava ilable in the 
local country language.  If  the assessment is not conducted for language reasons the outcome will 
not be measured for those subjects. 
9.8 Pharmacokinetics Assessment 
Actual sampling time -points will be recorded and used for PK calculations. If data permit, the 
following PK parameters for NA -1 will be calculated at the end of the study by standard 
noncompartmental methods for all subjects  with PK samples : 
•AUC 0–t: Area under the concentrati on-time curve from time zero to time of last measurable
concentration
•AUC 0–inf: Area under the concentration -time curve from time zero to infinity
•Cmax: Maximum plasma concentration observed after dosing
•Tmax: Time to occurrence of C max 
•t½: Terminal elimination half -life
Samples with no detectable NA -1 will be excluded from analysis (placebo).  A further analysis of 
the effect of administration of thrombolytic therapy (alteplase) on the pharmacokinetics of NA -1 
will also be performed. 9.9 Additio nal Assessments  
Two key concepts will also be explored in this trial: 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 52 of 88
1) The addition of a neuroprotectant to endovascular revascularization is feasible and can be
done with a CT to Thrombolysis in Cerebral Infarction Score ( TICI)3 flow in < 90
minutes.
2) Feasi bility of recruitment rate , defined by the recruitment in this multisite trial.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 53 of 88
10 ASSESSMENT OF SAFETY  
10.1 Adverse Event Definitions  
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting. 
Adverse Event:  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this trea tment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Therefore,  an AE may be: 
•A new illness
•The worsening of a concomitant illness
•An effect of vaccination, including the comparator
•A combination of the above
All AEs include serious and non- serious AEs.  
Pre-existing medical conditions are not to be rep orted as AEs. However, if a pre -existing condition 
worsens in frequency or intensity, or if in the assessment of the treating physician there is a change 
in its clinical significance, this change should be reported as an AE (exacerbation). This applies equally to recurring episodes of pre -existing conditions (e.g., asthma) if the frequency or intensity 
increases post -randomization. 
Serious Adverse Event:  
Serious and severe are not synonymous.  The term "severe" is often used to describe the 
intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as "serious," which is based on patient/event outcom e or action criteria usually 
associated with events that pose a threat to a patient's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  
A serious adverse event (or reaction) is any untoward me dical occurrence that at any dose: 
1)Result in death
2)Are life -threatening
3) Require or prolong inpatient hospitalization
4)Result in persistent or significant disability/incapacity, or
5)Are a congenital/birth defect
A SAE can also be an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. For example, any new 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 54 of 88
diagnosis of cancer (made after study enrollment) is considered an important medical event. 
Because our primary safety outcomes for the trial are also SAEs by definition, they will be reported dually as SAEs and as outcomes.  SAEs should be managed according to the best current standard 
of care.  
All deaths occurring during the follow up to Day 90 will be reported as an SAE.  When reporting a death, the event or condition that caused or contributed to the fatal outcome should be  reported 
as a single medical concept.  
Adverse Drug Reaction (ADR) 
In the pre -approval clinical experience with a new medicinal product or its new usages, particularly 
as the therapeutic dose(s) may not be established: all noxious and unintended responses  to a 
medicinal product related to any dose should be considered adverse drug reactions.  The phrase 
"responses to a medicinal products" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility,  i.e., the relationship cannot be ruled out. 
AE occurring within 30 days of randomization and all SAEs will be reported in the CRF.  S everity 
and relationship de finitions are presented  below.  
Table 10-1: Defin itions of AE -Related Terms  
AE Severity  
Mild:  Awareness of sign or symptom but easily tolerated.  
Moderate:  Discomfort sufficient to cause interference with normal activities.  
Severe:  Incapacitating, with inability to perform normal activities.  
AE Relationship  
Related  A clinical event, including laboratory test abnormality, where there is a 
“reasonable possibility” that the SAE was caused by the study drug, meaning that there is evidence or arguments to suggest a causal relationship. 
Probably:  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to drug administration, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on wi thdrawal.  
Possibly:  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to drug administration, but which could also be explained by concurrent disease or other drugs or chemicals.  Information on drug withdrawal may b e lacking or unclear.  
Unrelated:  This category is applicable to AEs which are judged to be clearly and 
incontrovertibly due to extraneous causes (diseases, environment, etc.) and do not meet the criteria for drug relationship listed for the above-mentioned 
conditions. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 55 of 88
Unexpected Adverse Drug Reaction 
An adverse reaction, the nature or severity of which is not consistent with the applicable product 
information (e.g., Investigator's Brochure for an unapproved investigational medicinal produc t).  
10.2 Cli
nical Management of Adverse Events  
10.2.1 Early Study Drug Cessation 
The intervention is the intravenous administration of 2.6 mg/kg  (up to a maximum of 270 mg)  of 
NA-1 over a 10 ± minute intravenous infusion to subject  undergoing endovascular mechanical 
thrombolysis/thrombectomy.  It is expected that dosing will be completed before the endovascular procedure is completed. However, if dosing is ongoing during the endovascular procedure, dosing will not be stopped in the event of an adverse intra- procedural event deemed to be a complication 
of the endovascular intervention. 
If any SAE is observed during dosing, dosing shall be immediately terminated.  If any moderate 
or severe AE is observed, the physician may terminate dr ug administration at his/her discretion.  
10.2.2 Treatment of Hypotension 
If hypotension (systolic < 80 mmHg; or any level of decreased BP that the physician deems to be 
clinically relevant) is observed in a subject, the hospital physician will be instructed, at his/her 
discretion, to administer any medication that they deem to be required for the subject ’s health and 
safety.  
There is no specific treatment requirement related to treating hypotension that may be observed in subjects with stroke who are also receiving NA -1. Treatment of emergent hypotension in this 
setting may include all or some of the following, as appropriate, and at the hospital physician’s discretion. 
First, the physician will determine if hypotension is symptomatic.   Asymptomatic subject s may b e 
observed for spontaneous recovery. 
•Treatment, if required, should include fluid resuscitation with crystalloid fluid  (e.g., 0.9%
saline) and/or vasopressors, if needed.
•Consider treatment with antihistamine agents (diphenhydramine 50 mg IV,  ranitidine
50mg IV ) and corticosteroids (e.g., Decadron™; 10 mg IV) if the reaction is severe.
•Consider using subcutaneous or intravenous epinephrine.
•If bronchospasm or laryngospasm are important additional symptoms, consider treatment
with inhaled racemic epinephrine.
Specific amounts and doses of intravenous fluids or other drugs administered are left to the medical 
judgment of the hospital physician. 
All subjects will be monitored closely for these and other potential complications throughout the 
clinical  trial.  All subjects will receive standard medical care as per local practice.      If hypotension 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 56 of 88
as defined above occurs, the hypotension and its treatment are to be recorded as an AE in the e -
CRF.  
10.2.3 Increases in Histamine  
NA-1 has undergone preclinical testing in rats, dogs, rabbits, and non- human primates.  When 
administered in these animals at doses higher than the one proposed in the current clinical trial, 
NA-1 has produced apparent anaphylactoid events characterized by histamine release in rats and 
dogs. The observed signs and symptoms were compatible with the physiological effects of histamine; specifically, transient hypotension and hives. This raises the possibility that anaphylactoid reactions to NA -1 could occur in humans. Patient susceptibility to drug -induced 
anaphylactoid events is highly variable. Therefore, potentially severe anaphylactoid reactions to the study drug may be encountered. Anaphylactoid reactions, including histamine -related reactions 
such as urticaria, bronchoconstriction, or hypotension, should be monitored.  In the event that an 
anaphylactoid reaction requiring treatment occurs, treatment should follow the same algorithms as would be followed if a spontaneous anaphylactoid reaction occurred in the community.  
•Follow emergency medicine ABCs  and establish airway first.
•Treat hypotension with crystalloid, colloid and/or vasopre ssors as needed (see Section
10.2.2).
•Consider treatment with antihistamine agents (diphenhydramine 50 mg IV, ranitidine 50
mg IV) and corticosteroids if the reaction is severe.
•Consider using subcutaneous or intravenous epinephrine.
•If bronchospasm or laryngospasm are important symptoms, consider  treatment with
inhaled racemic epinephrine.
10.2.4 Hyperglycemia  
In the Phase 1 study, 9% of all subjects receiving any dose of NA -1 (0.02- 3.75 mg/kg) had 
increases in blood glucose, as measured in their laboratory sample. However, in the Phase 2 study, there were no noteworthy differences between the NA -1 and placebo g roups in blood glucose 
across time and at no time point did greater than two subjects have a clinically significant abnormal 
blood glucose result in either treatment group.   
In this study, serum electrolytes and blood glucose will be drawn as per the schedule of 
assessments as well as part of the standard-of- care. If hyperglycemia is noted, the physician will 
treat the subject on a case- by-case basis. As there is no known relationship between NA -1 
administration and hyperglycemia (based on rat,  dog, and human studies), there is no unique 
protocol for blood sugar management following NA- 1 administration.  
10.3 Identification of Adverse Events by the Investigator 
AE monitoring and reporting will be followed -up until Day 30. SAEs will be followed through the 
final study exit visit (Day 90 Visit or death or end of study whichever is sooner) or until the subject 
is deemed “lost to follow -up”. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 57 of 88
AE identification while the subject is admitted to the acute stroke hospital will be collected via 
acute stroke hospital patient records and verbal histories from the subject or LAR.   For follow up visits after discharge from the acute stroke hospital the subject (or LAR if the subject is not able to respond to the questions) will be asked about the occurrence of AEs s ince the last contact, 
and if available, from records at the acute stroke hospital. 
AEs that were ongoing at the last contact will be updated with a stop date or confirmed as 
ongoing.  AE collection will continue until Day 30, and SAE to Day 90 or the fina l contact.  
A consistent methodology of eliciting AEs at all subject evaluation timepoints will be used.  Non-directive questions include: 
•How have you felt since your last clinical visit/hospital discharge?
•Have you had any new or changed health problems s ince you were last here?
•Have you had any unusual or unexpected worsening of your underlying medical conditionor overall health?
•Have there been any changes in the medicines you take since your last clinical visit/hospitaldischarge?
Diagnosis versus sign s and symptoms for the purpose of AE reporting: if known at the time of 
reporting, a diagnosis should be reported rather than individual signs and symptoms (e.g., record only pneumonia rather than pyrexia, coughing, shortness of breath).  However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis it is acceptable to report the information that is ultimately available.  
10.4 Reporting of A dverse Event s 
AEs should be reported as they occur on the e -CRF.  Documentation must be supported by an 
entry in the subject’s file.  Each event should be described in detail along with start and stop dates, severity, relationship to investigational product as judged by the Investigator, action taken and outcome. 
10.5 Reporting of Serious Adverse Events  
In order to comply with current regulations on SAE reporting to health authorities, the Investigator 
must document all SAEs regardless of causal relationship and notify the Sponsor . The Investigator 
will give access and provide the Sponsor with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product. It is the responsibility of the Investigator to request all necessar y documentation (e.g., medical records, discharge summary, 
autopsy) in order to provide comprehensive safety information. All relevant information must then be transcribed into the e- SAE Form.  
10.5.1 Reporting by the Investigator 
All SAEs must be reported to the Sponsor within 24 hour s of the local I nvestigator’s first 
awareness of its  occurrence.  SAEs will be reviewed by the trial medical monitor.  
The investigator will report the SAE s using the eSAE form in the eCRF , which will send an 
immediate alert to the Sponsor.  I f the eCRF system is not available, a paper SAE form should be 
directed within 24 hours to: 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 58 of 88
Pharmacovigilence, NoNO Inc. 
redacted
10.5.2 Repo
rting SAEs to the Health Authorities and Ethics Committees  
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the Sponsor’s standard operating procedures. 
SAEs that are assessed by the Sponsor to be unexpected and related to study drug ( expedited 
reporting  SAEs) will be reported to the regulatory agencies (i.e., Health Canada, European 
Medicines Agency and FDA) as per country requirements.  All  other SAEs will be reported to 
regulatory agencies based upon local reporting requirements. 
The S
ponsor’s medical monitor or designee will notify the Investigators in writing of the 
occurrence of any reportable SAEs.   The Sponsor or delegate will be responsible for reporting 
SUSARs to any Central Ethics Committees in compliance with local current legislation.  The 
Investigators will be responsible for informing the ir local  ethics committees of any reportable 
SAEs as per their local requirements.  
10.6 Addition al Safety Assessments 
All pre and post dose vital signs, biochemistry, hematology laboratory tests and 
electrocardiograms must be reviewed by the investigator or qualified designee.  Clinically significant results post dose will be recorded as an adverse event. 
10.6.1 Vital Signs  
Vital signs  (BP, HR) will be taken in the supine po sition at Baseline  (pre-dose) , at the completion 
of drug infusion, 24 Hours, 48 Hours and Day 5/ discharge.  Temperature will be taken at baseline 
per standard of care and reported on the CRF if available.  The Investigator will review the pre and 
post drug infusion vital signs.  If estimated weight was collected at randomization, the subject’s actual weight will be measured 
in hospital using standard hospital scales (i.e., stand up or in- bed scales  if the subject is not 
ambulatory ), as soon as possible, but within five days.  If actual weight cannot be measured for 
any reason (due to, for example severe illness  or unavailability of in-bed scales at the site ), weight 
will be determined by fir st asking the subject , second asking a family member or third by 
estimation.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 59 of 88
10.6.2 Bioc
hemistry and Hematology 
Blood work will be taken at baseline and at 24 hours  including :  CBC  (hemoglobin, platelets and 
hematocrit) , electrolytes  (sodium, potassium, chloride), INR, aPTT, serum creatinine and serum 
glucose.   This is  described in Section s 8.6. , 8.11 and the Schedule of Assessments. 
If the subject is female and is of childbearing potential, a pregnancy test (urine or serum point-
of-care pregnancy test) must be completed.   Clinically significant laboratory findings from the 
24-hour sample (post dose) will be recorded on the e- CRF as AEs.
10.7 12-Lead Electrocardiogram Monitoring . 
A 12- lead ECG will be performed at Baseline or, if the treating physician deems that an ECG 
will impede the subject’s access to care, within 6 hours of randomization, and at approximately 
24 Hours. Clinically significant findings  on the 24-hour ECG will be recorded on the e- CRF as 
AEs.  
10.8 Concomitant M edications  
Concomitant medications (Conmeds) will be collected from the time of randomization to the Day 
30 Visit/contact.  Conmed identification maybe collected via acute stroke hospital patient records 
or verbal histories from the subject or LAR.  Conmeds received while the subject is admitted to the acute stroke hospital will be identified from both hospital records and verbal histories.  
After discharge from the acute stroke hospital and for the Day 30 visit, the subject (or LAR if the 
subject is not able to respond to the questions) will be asked about medications taken since the last contact. Conmeds that were ongoing at the last  contact will be updated with a stop date or 
confirmed as ongoing at Day 30.    
10.9 Safety and Data Review 
In addition to the site investigator’s review and IDMC reviews, on a regular basis the sponsor and 
external medical monitor will conduct a blinded safet y and data review of the subject data collected 
to date in accordance with the Sponsor’s Safety Management Plan.  
10.10 Follow- up and Reporting of Pregnancies  
Pregnancy is an exclusion criterion for enrolment in this study, but a subject could potentially become pregnant during her participation. All pregnancy cases should be reported if they occurred 
during the study. To report the pregnancy case, the Investigator must fill out a Pregnancy Reporting Form and inform the Sponsor within one month of identifying a pr egnancy case. Study staff must 
then maintain contact with the subject to obtain information about the outcome —i.e., details about 
the delivery and the newborn, or about pregnancy termination—and must update the Pregnancy Reporting Form.  This information should be provided to the Sponsor within one month of delivery.  
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be considered as AEs, and in some cases,  could be considered SAEs. Spontaneous abortions, fetal 
death, stillbirth, and congenital anomalies reported in the baby are always considered as SAEs, 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 60 of 88
and the information should be provided to the Sponsor regardless of when the SAE occurs (e.g., 
even after the end of the trial).  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 61 of 88
11 STATISTICS  
11.1 Sample Size Considerations 
Assuming a 52% overall responder rate for the placebo group, there will be an approximately  80% 
power to detect an 8.7% absolute effect difference between response rate (proportion of 
responders, with Day 90 mRS in the range 0 to 2) with NA -1 and placebo, at alpha level 0.05, 2-
sided  with a planned sample size of 1076 evaluable subjects, randomized 1:1, per group, 
accounting for a single interim analysis when 600 subject  have reached their primary endpoint 
assessments, with O’Brien -Fleming a lpha-spending function (EaST® V6.3) stopping boundary for 
overwhelming efficacy and a non- binding 1% conditional power futility stopping boundary. The 
sample size will be inflated approximately 4% to N = 560 per group to account for loss- to-follow-
up and drop-outs.  
11.2 Analysis Populations 
11.2.1 ITT Population 
The primary efficacy analysis will be conducted in the ITT  population, defined as all subjects 
randomized into the trial with grouping by randomized treatment, regardless of treatment actually 
received.  Deceased subject  will be included in the ITT population with a mRS score of 6. An ITT 
analysis will also be co nducted for the secondary endpoints, with subject  grouped according to the 
randomized (intended) treatment. 
11.2.2 Per Protocol Population  
The primary analysis will be repeated on the Per Protocol (PP) population, defined to be all 
subject s randomized and treated , with no major protocol deviations. This population will be 
determined  via blinded review of protocol devi ations at the end of the trial before database lock 
and unblinding. 
Prior to unblinding , the imaging from each subject at the time of inclusion will be adjudicated to 
determine whether they have met the criteria for endovascular intervention, and hence for the trial. 
This will include review of baseline NCCT  and CTA .  Subjects  who do not meet the imaging 
criteria outlined in the trial inclusion/exclusion criteria, will not be included in the Per Protocol (PP) population. 
11.3 Analysis of Primary Efficacy Outcome  
The primary efficacy outcome for the pivotal assessment of efficacy for  regulatory purposes is the 
overall proportion subjects experiencing a favorable functional outcome 90- days post -
randomization, defined as 0 to 2  on the mRS . These subject s are defined as responders.   Subjects  
missing the day 90 primary assessment for any reason will be considered non-responders for the 
primary analysis (see Section 11.8).  The primary hypothesis to be tested is that administration of 
NA-1 will result in an increase in the proportion of subjects with independent functioning on the 
mRS (as defined by a score of  0-2) at Day 90.  The primary analysis will be a Wald test for 
treatment group difference in the primary outcome from a logistic regression adjusted for the 2 
stratification variables ( alteplase use, first declared thrombectomy device)  and the 6 covariates  
used in the minimization :  Age,  sex, baseline NIHSS score, baseline ASPECTS  score, occlusion 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 62 of 88
location   and site . This will be conducted on the ITT population at the 2-sided  5% significance 
level overall (for the trial), adjusted for the interim analysis per the O’Brien -Fleming boundary 
spending function. 
Three supportive analyses to the primary analysis will be conducted: (1) the primary analysis 
reapplied to the Per Protocol  population; (2) a re -randomization analysis to demonstrate that 
minimization did not bias the primary endpoint analysis and (3) The primary  analys is will be 
repeated  on the PP population using actual first endovascular approach (instead of declared 
approach ). Details of these are provided in the Statistical Analysis Plan.  
11.4 Key Secondary Outcome Analysis 
The study will also test the secondary hypothesis that among randomized subject , those who are 
treated with NA -1 will show shift in the distribution of scores  on the mRS scale at 90 days, 
assuming that categories 5 and 6 (bedbound with severe disability, and death) are collapsed.  This secondary outcome will use an adjusted proportional odds model to derive the common odds of 
improvement (“shift”) along the mRS  scale.  Adjustment will include all of the variables in the 
stratification and minimization algorithm (age,  sex, baseline NIHSS score, baseline ASPECTS 
score, occlusion location, intravenous alteplase treatment , declared first endovascular approach  
used and site). The proportional odds assumption will be tested. 
The choice of the shift analysis is based upon empirical evidence that the mRS scale, when categories 5 and 6 are combined, is a true interval scale meaning that any one step increment in the scale is the same; thus, it is unlikely that the proportional odds assumption will be violated and clinical step changes across the scale are meaningful.
42  The proportional odds approach to analysis 
of the mRS scale was applied in the ESCAPE trial.3,43  It allows us to include elderly subject  (who 
have a poorer prognosis irrespective of treatment) because a shift from severe to moderate disability will still be recogniz ed as an important outcome. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 63 of 88
Figure 2: Projected outcome by mRS category based  data from the ESCAPE trial and 
estimation of NA- 1 effect based on the minimal clinically important difference.  
Predi
cted outcomes by mRS category in the control group are from the ESCAPE trial.3  This 
shows an average 2-3% improvement in outcomes within each mRS category. 
If the distribution of subject  follows that shown in Figure 2  (i.e. optimally shows a shift across the 
full scale  with common OR 1.32), simulation (n= 5000 iterations) demonstrates that the power will 
be 97.2% to show a common OR of 1.32 with 1076 evalua ble subject.  
All tests will be conducted with two-sided level of significance alpha = 0.05.  A fixed sequence 
multiple testing procedure will control the overall experiment- wise error rate for the trial (see 
below).  It pre- specifies that, with all tests conducted at the same pre -specified significance level, 
the primary endpoint will be tested  first and all subsequent tests are considered failed and 
deemed exploratory if conducted, in the order specified (primary analysis first, key secondary 
analysis second, etc.), after the first test which fails.: All tests after the first failed test are considered exploratory. For the purpose of clarity, since the key secondary analysis of the ordinal 
mRS scores will employ a proportional odds model (POM), if the proportional odds assumption fails, this key secondary analysis will not be performed, and the remaining secondary tests will still be considered to be protected. 
The fixed sequential order for testing in the ITT trial population is: 
1)Primary efficacy outcome
2) Key secondary outcome analysis (shift analysis using proportional odds model);
3)Secondary efficacy endpoints, as specified in the order presented below in Section 11.5.
11.5 Analysis of Secondary Efficacy Outcomes  
The key secondary outcomes will be tested in the following order:  
1. Shift analysis of 90 day mRS under proportional odds model across the mRS scale , as
described in Section 11.4 above.
2.The NIHSS 0-2 vs. 3 or greater at 90 days.
3.The BI at 95 -100 vs. 0- 90.
4.The mortality rate at 90 days.
5. The proportion of subjects with mRS score of 0-1 at Day 90.
1517
2023
1722
1612
1513
75
108
0 20 40 60 80 100ControlNA1
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 64 of 88 
 11.5.1 Modified Rankin Scal e – Shift Analysis  
The mRS shift analysis will be conducted as described in Section 11.4 above. 
11.5.2 National Institutes of Health Stroke Sca le 
The NIHSS scores will be dichotomized into 0- 2 (indicating a good neurological outcome) versus 
>2 (indicating otherwise). The proportion of subject  achieving a good neurological outcome at 
Day 90 or the last rating in NA -1 versus placebo control subject s will be compared using the same 
logistic regression model as in the primary efficacy.  
11.5.3 Barthel Index  
The BI scores will be dichotomized at 0 -90 (indicating otherwise) versus 95- 100 (indicating 
independent functioning with activities of daily living).  The proportion of subject  with 
independent functioning with activities of daily living at Day 90 in NA -1 versus  placebo control 
subjects will be compared using the same logistic regression model as in the primary efficacy.  
11.5.4 Mortality Rate  
Mortality rates, as defined as the number of deaths observed divided by the number of subject  
observed over the 90 day study period between NA -1 and placebo control subjects, will be 
analyzed by the same logistic regression model as in the primary efficacy . 
11.5.5 Modified Rankin Scale – 0-1 Dichotomy Analysis 
The mRS scores will also be dichotomized into 0 -1 (indicating freedom from disability) and > 1 
(indicating otherwise). The proportion of subject  with freedom from dependence/disability at Day 
90 in NA -1 versus placebo control subjects will be compared using the same logistic regression 
model as in the primary efficacy.  
11.6 Analysis of Tertiary Efficacy Outcomes  
11.6.1 EQ-5D-5L 
For the EQ-5D- 5L, the difference between NA -1 and placebo control subjects in the distribution  
of the index and VAS scores on these scales at Day 90 will be presented descriptively. 
11.6.2 Volume of Stroke 
The total volume of new a) DWI and b) FLAIR lesions in NA-1 versus placebo control subjects 
will be calculated using a linear regression using a cubic root transformation.  Total volume will be assessed using a linear regression using a cubic root transformation if needed. An ANCOVA 
will be fit and summarized . 
Specific covar iates are listed in  Section 11.7.  
11.6.3 Cognitive outcomes 
These will be explo red using the BNT15, SNAP and the MoCA. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 65 of 88
11.6.4 mRS at 30 Days 
The overall proportion subjects experiencing a favorable functional outcome 30- days post -
randomization, defined as 0 to 2 on the mRS.  
The tertiary and all other analyses will be considered exploratory.  Details of the methods of 
analysis will be finalized  in the SAP prior to the first IDMC meeting.  
11.6.5 Pharmacokinetics  
Descriptive statistics will be calculated for plasma concentrations and for all PK parameters (NA-1). In addition, dose proportionality and linearity of dose dependent PK parameters will be 
investigated. Individual and mean plasma concentration versus time curves will be plotted on linear and semi -logarithmic scales. Plasma concentration versus time curves will be labelled 
appropriately with treatment regimen and batch number. 
11.7 Adju
stment for  Covariates and Subgroup Analyses  
In addition to the primary and secondary analyses adjusting for age, sex, baseline NIHSS score, 
baseline ASPECTS  score, occlusion location , intravenous alteplase  use, declared first 
endovascular device and site, exploratory analyses will be conducted to determine the potential 
roles of common baseline characteristics  and assess potential heterogeneity of treatment effect 
across subgroups .  Specific subgroups of interest include the very elderly (age > 80 years), m en 
vs. women, subject  with different baseline stroke severity (on NIHSS and measured radiologically 
on ASPECTS), subject  treated with intravenous alteplase (yes/no ), declared first endovascular 
approach , baseline occlusion location (MCA vs. ICA), and subject with long/short time from onset 
to treatment.  Full details will be specified in detail in the SAP.  
11.8 Handling of Missing, Unused and Spurious Data  
Every effort will be made to keep missing data, particularly the Day 90 outcome assessments, to a minimum.  However, some missing data may be inevitable due to, for example, loss to follow -up.  
This was kept to a minimum of 1 .3% in the ESCAPE trial
3. Deceased subject  will score 6 on the 
mRS and be counted as non- responders. For the primary analysis for regulatory submission, we 
will assume that subject  missing the primary endpoint data will be considered to be non-
responders. Sensitivity analyses using various imputation  techniques will be specified 
prospectively in the SAP before the databas e lock for the interim analysis  if more than 5% of 
subject  randomized are missing the primary endpoint. 
11.9 Analyses of Safety 
The safety pop ulation will consist of all subjects who received any dose of study drug. The main 
analyses will be frequency of SAEs and 90- day mortality.   It is expected that the safety population 
and the ITT population will be near -identical.  
11.9.1 SAEs  
SAEs over the 90- day study period will be summarized by presenting, for each treatment group, 
the number and percentage of subjects having a t least one S AE, having an SAE in each body 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 66 of 88
system and preferred term , by s everity and relatedness to study medication. T he frequencies and 
incidences of SAEs occurring in subjects in the drug and placebo control groups will be 
summarized within treatment group by the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC). The frequencies and incidences of SAEs and 
discontinuations due to SAEs occurring in subjects in the NA -1 and placebo control groups will 
be summarized within treatment group . 
11.9.2 Mortality  
Event rate (%) for mortality over the 90 -day study period between NA -1 and placebo control 
subject s will be compared by logistic regression. The logistic regression model will include factors 
for treatment group.  All deaths will be provided in a listing. 
11.9.3 AEs 
Additional analyses will consider the frequency of AEs and discontinuations due to AEs. AEs wi ll 
be summarized by presenting, for each treatment group, the number and percentage of subjects 
having any AE, having an AE in each body system and preferred term. Severity and relatedness to 
study medication will be recorded  according to Table 10-1. The frequencies and incidences of AEs 
occurring in subjects in the drug and placebo control groups will be summarized within treatment group by the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC). 
11.9.4 Vital Signs  
Absolute values and changes for vital signs from pre-dose to Day 5 or discharge  will be 
documented. The maximum deviation of BP from Baseline between drug and placebo control 
groups (systolic and diastolic) to 24 Hours will be analyzed using ANCOVA, including factors for 
treatment gr oup. 
11.9.5 Laboratory and 12- Lead ECG Results  
Absolute values for laboratory results and generalized 12-lead ECG results (i.e., normal, sinus 
bradycardia, etc.) will be documented descriptively.    
11.9.6 Prior and Concomitant Medications  
Prior and concomitant medications will be listed per patient, with the listings separated  within 
treatment group . 
11.10  Independent Data Monitoring Committee  
An IDMC will perform periodic safety reviews of the clinical data. The reviews will occur  when  
100, 300 and 600 subject s have reached their Day 90 final study visit.  
An efficacy interim analysis after approximately 600 subjects complete the Day 90 follow -up will 
be conducted using the alpha spending function method
1 with O’Brien and Fleming2 type stopping 
boundary for efficacy and a  non- binding conditional power boundary for futility.   The trial may 
be stopped for overwhelming efficacy  or for futility  at the interim analysis if the test statistic 
crosses the O -F or conditional power boundar y.  The IDMC charter will describe, among other 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 67 of 88 
 things, the approach to handling overwhelming efficacy, futility, and potential imbalance in key prognostic variables.  
To prevent operational bias all interim results on safety and efficacy will be reported only to the 
IDMC, keeping the sponsor, project team, investigators and subject  blind to results by treatment 
assignment during the study. Firewalls will be in place at the Statistical Analysis Center preparing all interim reports to protect and sequester all interim results on safety and efficacy. This will be detailed in the IDMC Charter.      
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 68 of 88
12 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
The sponsor or delegate will be permitted to visit the study facilities at any reasonable time in 
order to maintain current, detailed knowledge of the study through review of the records, source 
documents, observation, and discussion of the conduct and progress of the study.  In addition, the sponsor will maintain regular telephone and written communication with all investigators  through 
the co ordinating centre . The sponsor  (or delegate)  will be given complete access to all components 
of the study facility that pertain to the conduct of this study, and may be present to observe any aspect of the conduct of the study by medical and  paramedical staff, including but not limited to 
drug preparations, dosing, sample collections, and clinical observations.  E -CRFs will be 
monitored with sufficient frequency to assess the following:  Subject randomization, compliance with protocol procedu res, the completeness and accuracy of data entered into the e- CRFs, 
verification of e -CRF data against original source documents, and occurrence of AEs.  Adequate 
time and all documents for these monitoring visits must be made available by the investigator s.  
The investigators will permit trial- related monitoring, audits, REB/IRB review, and regulatory 
inspections, providing direct access to source data/documents.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 69 of 88
13 QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure monitoring responsibilities are performed to the fullest extent possible, industry 
experienced study monitors will perform on site data verification for the trial.   All data monitored 
on site are verifi ed for accuracy and completeness using source documents for all subjects.  In 
addition, 100% of subjects enrolled are monitored for the presence of signed consent and Health 
Insurance Portability and Accountability Act ( HIPAA ) and Personal Information and Portable 
Electronic Documents Act ( PIPEDA ) documentation, where applicable.  
Monitoring of the investigational sites will be conducted by the sponsor or contracted to a qualified CRO.  The sponsor will determine the extent, nature, and frequency of on- site visits that are needed 
to ensure that the study is being conducted in accordance with the approved protocol (and any amendments), GCP, and all applicable regulatory requirements. At site visits, the monitor will, as required, assess the progress of the study; check that the study data chosen for verification are authentic, accurate, and complete; ve rify that the safety and rights of patients are being protected; 
compare original documents with data entered into the study database; and identify any issues and address their resolution. 
The investigator agrees to allow the monitor (s) direct access to al l relevant documents , and to 
allocate his/her time and the time of staff to discuss findings , corrective actions  and any relevant 
issues. In addition to contacts during the study, the monitor may also contact the site prior to the 
start of the study to dis cuss the protocol and data collection procedures with site personnel.  
Additional on- site monitoring verification includes: ongoing evaluation of the adequacy of site 
facilities and staff, site recruitment, subject randomization, the presence of regulatory documents, 
and specific review of documents and data.   The initial performance -monitoring visit to a site takes 
place after the initial subject(s) are enrolled and will continue according to enrolment for the duration of the trial. 
During the monitoring visit, any omissions and corrections to da ta submitted to the database will 
be noted and queries will be generated by the monitor and resolved by the site.  The close -out monitoring visit by the  monitor will take  place at the completion of subject 
enrollment and protocol required follow -up visits at the performance site.  At that visit, the monitor  
will again review  the presence of a regulatory file and verify  documents for currency and 
completion as  directed by t he CRU.  Sites will be  instructed in the record retention of all trial 
documents. Principal Investigators are directed to close the trial and issue a final report to the 
IRB/REB. Finally, any additional special considerations for the auditing of any additi onal safety 
issues are made during this final monitoring visit.  
Except for an emergency situation in which proper care for the protection, safety and well - being 
of the study subjects requires medical treatment, the study will be conducted as described in the 
approved protocol, ICH-GCP, SOPs and regulatory requirements.  All medical treatments will be 
recorded.  Any deviation(s) from the protocol will be recorded and presented in the final clinical study report.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 70 of 88
13.1 Audits and Inspections  
In accordance with the  principles of ICH E6 Guideline for Good Clinical Practice, the study site 
may be inspected by regulatory authorities and/or audited by NoNO Inc. Quality  Assurance (QA) 
or their designates. The investigator and relevant clinical support staff will be required to be 
actively involved in audits and inspections, including staff interviews, and to make all necessary documentation and data available upon request. 
During the course of the study and/or after it has been completed, one or more investigator site 
audits may be undertaken by auditors from NoNO QA or delegates. The purpose of these audits is 
to determine whether or not the study is being/has been conducted and monitored  in compliance with 
recognized ICH E6 Guideline for Good Clinical Practice, protocol and approved amendment 
requirements, applicable local SOPs, and local laws and regulations. It is the responsibility of the investigator and site staff to promptly address, by coordinating with NoNO Inc.  any deficiencies 
stemming out of regulatory inspections and NoNO QA or delegate audits, and to ensure that 
agreed -upon corrective and preventive actions are implemented as soon as possible. 
An inspection by any regulatory authority may occur at any time during or after completion of the study. If an investigator is contacted by a regulatory authority for the purpose of conducting an inspection or to discuss any compliance issues, he/she is required to contact NoNO Inc 
immediately.  
13.2  Pr
otocol Amendments and Revisions  
Should amendments and/or revisions to the protocol be required, they will be originated and documented by the sponsor. All amendments and/or revisions will be made in compliance with sponsor SOPs. All amendments will be submitted to the REB/IRB for approval prior to implementation . 
It is the sponsor’s responsibility to submit all revisions and amendments to regulatory authorities when  necessary.  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 71 of 88
14 ETHIC
S 
14.1  Research Ethics Board/Institutional Review Board 
This study will be conducted in substantial compliance with the principles and requirements of the 
ICH-GCP , Canadian Food and Drug Regulations, United States Code of Federal Regulations 
(CFR; including Title 21 Parts 50, 54, 56, and 312), the Declaration of Helsinki and the Canadian 
Tri-Council Policy Statement on Ethical Conduct for Research involving Humans (2), where 
applicable.  
This protocol and the consent forms will be submitted to each hospital’s REB/IRB. Before initiation of the study, a copy of the REB/IRBs’ approval letters will be provided to the sponsor and the membershi p list of the REB/IRB will be kept on file.  
This protocol and the informed consent document and any subsequent modifications will be 
reviewed and approved by the REB/IRB  responsible for oversight of the study.  For subjects who 
cannot consent themselves , an LAR may sign the consent form.  The consent form describes the 
purpose of the study, the procedures to be followed, and the risks and benefits of participation.  A 
copy of the consent form must be given to the subject and/or  the LAR; and this fact must be 
documented in the subject’s record.  SAEs will be reported to the REB/IRB according to their requirements.    
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 72 of 88
15 DATA HANDLING AND RECORDKEEPING  
15.1 Data Handling 
The database used in the study will be a 21 C FR Part 11  compliant database. During the trial, 
clinical data reported in the eCRFs will be integrated into the clinical database under the 
responsibility of the Sponsor or their qualified representative. Quality control in the form of computerized logic and/or consistency checks will be systematically applied in order to detect errors or omissions.  
In addition, safety reviews may be performed several times by the Sponsor’s staff in the course 
of the trial. Any questions pertaining to the reported clinical data will be submitted to th e 
investigator for resolution. Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
After integration of all corrections in the complete set of data, the database will be released for 
statistical analysis.  
15.2 Investigator Files/Retention of Documents  
The Inves tigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should be 
classified into two different separate categories: (1) Investigator's Study File; and (2) Subject 
Clinical Source D ocuments. 
The Investigator 's Study File will contain the Protocol/A mendments, CRFs , REB/ IRB and 
governmental approval with correspondence, all versions of ethics approved informed consent  
forms , staff curriculum vitae and authorization forms and other appropriate 
documents/correspondence, etc.    
Subject  clinical source documents (usually defined by the project in advance to record  
efficacy/safety parameters independent of the CRFs) would include subject  hospital/clinic records, 
physician's and nurse's notes, appointment book, original laboratory reports, ECG, X -ray, 
pathology and specia l asses sment reports, signed consent form s, consultant letters , and source 
worksheets . The investigator must keep these two categories of documents on file according to 
local clinical trial regulation .  In Canada, all study documents for a regulated trial require  storage 
for 25 years.  After that period of time the documents may be destroyed, subject to local regulations. 
The Investigator and the sponsor will maintain the records of disposition of the drug and the clinic 
records in accordance with ICH -GCP and each  applicable regulatory agency.  Clinic records will 
be retained at the site until informed by the sponsor to destroy the documents.  If the clinical study must be terminated for any reason, the investigator will return all study materials to the sponsor and provide a written statement as to why the termination has taken place and notify the REB/IRB.  
15.3 Source Documents and Background Data  
Any i nvestigators shall supply the sponsor, upon request, with any required background data from 
the study documentation or  clinic records. This is particularly important when e -CRFs are illegible 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 73 of 88 
 or when errors in data transcription are suspected. In case of special problems and/or governmental 
queries or requests for audit inspections, it is also necessary to have access to the complete study 
records, provided that subject  confidentiality is protected.  
15.4 Case Report Forms  
For each subject  randomized, a n electronic CRF must be completed and signed by the i nvestigator. 
If a subject  withdraws from the study, the reason must be noted on the CRF.  
All forms should be completed within five business days of subject  visit.  
All corrections will be tracked in the eCRF audit trail. The Investigator should ensure the accuracy, 
completeness, legibility, and timeliness of the data repo rted to the s ponsor in the CRFs and in all 
required reports. 
15.5 Confidentiality  
All imaging, evaluation forms, reports, and other records that leave the site are identified only by 
the site and subject number to maintain subject confidentiality.  All records are kept in a locked file cabinet. Clinical information is not released without written permission of the subject, except as necessary for monitoring by REB/IRB , Health Canada, the sponsor, or the sponsor’s designee.  
All study investigators at the clinical sites must ensure that the confidentiality of personal identity and all personal medical information of study subject s are maintained at all times.  Federal 
legislation in Canada (PIPED A), and provincial legislation [ e.g. Health Information Act ( HIA) in 
AB] where applicable, must be followed.  Additionally, any U.S. clinical sites must follow privacy 
obligations to study subject s under HIPAA .   European or Asian/Australasian sites must conform 
to local privacy and confidentiality law and custom.  On the CRFs  and other study documents or 
image materials submitted to the CRU, the subjects are identified only by study identification codes.  
Personal medical information may be reviewed for the purpose of verifying data recorded in the CRF by the site monitors.  Other properly authorized persons, such as the regulatory authorities, may also have access to these records.  Personal medical information is always treated as confidential. 
  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 74 of 88
16 PUBLICATION AND PRESENTATION POLICY 
A trial executive committee shall be formed, and include at least the trial principal investigator 
and co -principal investigator, the statistical consultant, and representatives of the Sponsor. The 
trial executive committee will be co -authors on all publications and presentations.  The primary 
author list for the primary publication will consist of the executive committee and the site principal /qualified  investigator at each of the sites.   A formal publication policy will be presented 
and developed by the trial execut ive  
17 ANCILLARY STUDIES POLICY 
Ancillary or sub- studies may be considered by the trial executive committee.  Important 
principles that guide the addition of ancillary studies  are: 
1) No subject  shall be enrolled in a concurrent investigational drug/device trial during the
study period
2) Concurrent enrollment of an ESCAPE -NA1  study subject  in a site specific  observational
cohort study is allowable, where the following conditions are met:
a.The executive committee is notified
b. The concurrent study does not interfere with any study follow-up procedures or
potentially confound the outcome of the ESCAPE -NA1  trial
c.The site principal/qualified investigator  of the concurrent study explicitly
acknowledges that the treatment given in the ESCAPE -NA1  trial may confound
the outcome of the site- specific concurrent study
d. T he subject  may not be included in any publication or report until the ESCAPE -
NA1  study has been concluded
3) Ancillary or sub- studies shall be vetted and approved by the trial executive committee.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 75 of 88
18 DATA- SHARING PLAN 
The s ponsor will permit any and all academic publications arising from th e trial data provided that 
no publication containing unblinded trial data precedes publication of the overall trial results in a 
peer-review journal , and are (1) approved by the trial executive committee and (2) the publication 
authors notify the sponsor at l east 30  days prior to submittal for publication with a copy of such 
proposed publication for the sponsor’s review and comment. Employees or consultants of the 
sponsor will only be named as authors in any such publication if the parties agree that it is 
appropriat e under the usual conventions used by academic institutions for naming authors in 
scientific publications.  Upon request of the sponsor the publication or disclosure shall be delayed 
for up to 60 days in order to allow for the filing of a patent applicatio n.  
The Executive Committee will make the trial results available as free -access using PubMed  and 
on Clinical Trials.gov (www.clinicaltrials.gov).  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 76 of 88
19 FINANCIAL CONSIDERATIONS  
Routine care is expected to be paid for by the existing standard medical insurance system.  This 
will include but is not limited to:  
•Admission to hospital
•Baseline laboratory testing, pregnancy test, ECG, baseline NCCT and CTA , baseline
CTP
•Endovascular procedure and angiography
•Follow-up limited -sequence MR brain imaging a t 24 Hours
•Follow up ECG at 24 H ours
•Follow-up laboratory testing (other than the mandated tests at 24 hours)
•Phys
ician fees
•Treatment processes in the endovascular lab since they are considered standard of care
•Stroke unit care in hospital
•Nursing care
•Rehabilitation and home care if relevant
•Outpatient clinic follow -up at 90 days (routine)
The study fees are designed to cover the costs of study personnel, data collection, research study processes  and treatments , the 30-day follow up visit, the 90-day follow-up visit , CRF 
completion, adverse event reporting, concomitant medication reporting, submission of imaging to the core lab .  The study fees are inclusive of any local institutional overhead/indirect costs. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 77 of 88
20 Appendix  1 – Additional Guidance on Imaging Selection and Endovascular Treatment 
Notes on Eligibility for Endovascular Therapy 
Eligibility  for endovascular treatment has been defined by the recent randomized clinical trials. 
Guidance on selection of subject  using imaging is as follows: 
Exclude subject  with evidence of a large core of infarction  (ASPECTS 0 -4), evidence of very poor 
intracranial collaterals on CTA : 
•A large core can be defined as a baseline NCCT reveals a moderate/large core defined as
extensive early ischemic changes of ASPEC TS 0 -4 in the territory of symptomatic
intracranial occlusion.
•Poor collaterals can be defined on a multiphase  or dynamic  CTA: no or minimal collaterals
(ie. equivalent to a Tan score 0 or 1 ).  Poor collaterals can be similarly defined on single
phase CTA but with reduced specificity compared to CTA .  Multiphase or dynamic CTA
is required for the study.
We advise using the ESCAPE3 imaging criteria for selection of subject into the trial.  
Angi
ographic Process Measures  
Short imaging time: 
The total imaging time starts from the time the subject  reaches the door of imaging suite to when 
the subject  is out of there and ready to move to next step. It includes putting subject  on table, 
setting intravenous line, connecting to pump, etc. In the case of MR it would include the time taken 
to exclude pre sence of pacemaker etc.   It includes post -processing time.  Imaging time should not 
exceed 15 minutes.  
Excellent overall organization to reduce CT -to-groin puncture time : 
There are multiple steps to get from imaging to the groin puncture and these may inc lude:  
•Image interpretation
•Blood draw
•ECG
•Anesthesia involvement for conscious sedation
•Prepping the angiography suite
•Availability of nurse and technician
•Availability of respiratory technician and anesthetist if appropriate
•Ability to move the subject from the CT suite rapidly to the interventional suite
Groi
n puncture -to-recanalization time:  
From the time  the subject  is on angiography suite table:  
•Pre-plan your procedure, catheters required by reviewing the CTA of the arch
•Puncture the groin while the subject  is getting draped.  Do not wait.
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 78 of 88
•Have a stroke kit ready .
•Have a pre-decided division of labour: who is going to do what?
•Simple things like shaving the groin: is it needed?
•Foley catheter.  Draining the bladder improves subject  comfort and help reduce BP
•Assess need for anesthesia; overall general anesthesia should be avoided.  Involvement of
an anesthetist for conscious sedation is ideal.
•Training on use of other drugs to hold subject  still: consult with local anesthetist .
•8F sheath .
•Go straight to vessel of interest.
•Choice of catheter dependent on CTA .
•Whether common carotid artery  run needed on not dependent on CTA.
•Try to use standardized microcatheter and wire.
•Plan an entire kit of stuff that is needed included things like a 60 cc syringe.
TICI
2c or 3  flow: 
Aim for complete recanalization [Thrombolysis in Myocardial Infarction ( TIMI ) 3] and 
reperfusion (TICI 3) .  A few small distal e mboli are an acceptable outcome and are generally 
tolerated well by collateral flow.  
Control BP: 
Whil e the artery remains occluded, systolic blood pressure (SBP)  150 or greater is probably useful 
in promoting and keeping collateral flow adequate.  Indirect evidence supports this assertion.  Once 
reperfusion has been achieved, BP often falls naturally.  Controlling BP once reperfusion has been 
achieved aiming for a normal BP for that individual is sensible.  Labetalol or an intravenous β-
blocker such as metoprolol in low doses is preferred. 
Keep complication rate low : 
Be prepared to stop and back out.  Do not take unnecessary risks.  Remember that you do not 
necessarily need a “perfect” angiographic outcome to have a good clinical outcome.  
Medical Management : 
Designate one person to observe and manage the subject ’s vital signs.  Follow the oxygen 
saturation ( SaO 2), puls e and BP.  Manage accordingly.  In an ideal circumstance, an anesthetist 
helps manage this aspect of care.  
In the absence of an anesthetist, the standard of care is that the attending neurologist or stroke fellow will have a lead apron on and be in the ne uro-angiosuite managing the medical and 
neurological condition of the subject . 
BP management is described above.  There are no clear guidelines that are based upon level 1 
evidence.  
Conscious Sedation Management : 
We strongly recommend that all sites avoid general anesthesia.  The vast majority of endovascular stroke treatment can be completed under conscious sedation.  Several case series support the 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 79 of 88
concept that general anesthesia is associated with poorer outcomes.  A possible explanation is 
prolonged BP  lowering resulting in more rapid progression to infarction. 
A simple conscious sedation paradigm for adult subject  is as follows:  
•2.5 mg midazolam IV
•25-50 µg fentanyl IV
These
 drugs should be given together since this avoids the occasional paradoxical agitation seen 
with intravenous benzodiazepines alone.  They can be given q10- 15min.  Follow the RR and SaO2 
to avoid trouble with respiratory suppression.  Managing conscious sedation can be done by the neurologist or stroke fellow in the room.   
It is of ten additionally helpful to pre- treat subject  with anti- nausea agents:  
•25-50 mg dimenhydrinate (gravol) IV [available in Canada, not the US]
This drug is very mildly sedating and may help avoid an episode of aspiration. The only subject  who typically will require intubation include those with paradoxical agitation 
associated with a Wernicke’s aphasia, or those who develop respiratory compromise due to 
aspiration or other event arising after randomization. 
Carot
id artery stenting : 
It is recommended as a guideline that carotid artery stenting is should not be done  as part of the 
treatment in the study.  Tandem occlusion of the extracranial carotid at the bifurcation associated 
with an M1- MCA occlusion is common.  Patients with tandem occlusions are eligible for 
enrolment.  The target lesion initially is the M1 -MCA occlusion.  Advance a catheter past the I CA 
lesion and deal with the M1- MCA first.  Very often, in this process, the proximal ICA is open at 
the end of treating the M1- MCA because of the mechanical manipulation of the occlusive lesion 
at the carotid.  What was initially a 99% stenosis is reduced to 60 or 70%. 
At this point stop.  Treat the subject  with ASA per rectum (since they cannot swallow) and bring 
the subject  back the following day to decide on whether subsequent procedures are necessary .  It 
is simply not necessarily true that forward flow  in the carotid is required to keep the M1- MCA 
open. The major potential difficulty with leaving a carotid stent in place is the need for antiplatelet 
therapy, which will increase the chance of major symptomatic bleeding.  
If, despite the above, the treating physician deems that a stent is required – either intracranially or 
at the carotid bifurcation  because this action is in the patients’ best interest , we recommend using 
ASA and clopidogrel rather intravenous abciximab or eptifibatide.  Give ASA per rectu m and as 
soon as possible give 600 mg clopidogrel per NG. 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 80 of 88
Use of IA medications : 
Use of intra -arterial medication such as alteplase, abciximab, epitifibatide, tirofiban is  not advised  
although nothing in this protocol forbids the use of any treatment that the treating physician deems 
to be in the subject’s best interest. Any  such medications will be noted in the CRF . Note that 
alteplase is not indicated for direct IA catheter delivery.   
Numb
er of Devices / GP2b3a Inhibitors / When to stop: 
Some lesions are too difficult to treat and adequate recanalization may not be achieved.   The more 
devices that are used  and the most antithrombotic agents that are used, the greater the risk of major 
AEs.  Use of intravenous GP2b3a inhibitors in the setting of AIS, is associated with a very high 
risk (up to 40%) of hemorrhage.  Please do not use them.  Please make every effort to achieve recanalization within 90 minutes of imaging.  If this is clearly not going to be achievable, the interventionalist and  team must make a judgment as to whether to continue.  Spending more than 
90 minutes working on an intracranial lesion is a recipe for major AEs.  
Chasi
ng distal M2, M3 or A2, A3 occlusions: 
Once the arterial occlusive lesion is open, there will remain visible distal occlusion approximately 
10-20% of the time.  Do not chase these.  Do not give regional alteplase  infusion.  A perfect
angiographic outcome is not necessary for a good clinical outcome and there is a greater risk ofdoing harm.
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 81 of 88 
 21 Appendix 2: De rivation of ASPECTS on NCCT  and Collaterals Scoring on CTA 
Minimal Acceptable Quality for CT scan  
There is potential for variation across sites as to the choice of  imaging modalities that treating 
physicians use for deciding appropriate subject for intervention.  Overall, CT is the  mainstay for 
this trial and all patients must be selected on the basis of CT and multiphase or dynamic CTA, to standardize imaging patient selection criteria.  
• NCCT  
• CTA  from arch to head 
NCCT quality 
• Minimum power: 120-140 kV, 170-200 mA  
• Two second scanning time 
• 5 mm section thickness 
• Appropriate algorithm reducing bone artefacts and high SNR for gray- white 
differentiation  
• Contiguous axial sections from skull base to vertex parallel to the inferior or bitomeatal 
line (IOML)  
• A good quality stroke protocol scan is defined by the following two criteria on the unaffected side:  Lateral margin of the lentiform nucleus well discriminated in the absence of previous infarction. 
• Insular ribbon is well defined in the absence of previous infarction. 
• CTA should use minimum contrast media –75cc is the recommended amount  
• Helical acquisition  
• Reformats should include:  thin (3mm) axial, sagittal, coronal maximum intensity 
projection (MIPS), thick (25 mm) axial and sagi ttal MIPS  
NCCT   
NCCT shall be scored using ASPECTS , a 10-point score derived by examining each of 10 regions 
on the middle cerebral artery territory.  Ischemic change present is scored as 0; ischemic change 
absent is score as 1.  Adding up the score gives a maximum of 10 (favourable scan) and minimum of 0 (unfavourable scan). 
The score is highly reliable when trichotomized into 0- 4 (severe ischemic change, large core), 5 -7 
(moderate ischemic change) and 8 -10 (minimal ischemic change, small core).  ASP ECTS may be  
less reliable early in stroke (i.e. within 90 minutes of onset); however, at later time windows it 
should be easy to recognize large areas of irreversible damage.  Having a good quality scan and optimization of scanner is key  to successful inte rpretation .  Further information is available at:  
www. aspectsinstroke.com . 
CTA  
The importance of contrast bolus timing should be emphasized.  Using single -phase CTA, it is 
important to have a sufficiently venous weighted study to be able to visualize the collateral 
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 82 of 88
circulation adequately.   The CTA must include the aortic arch to allow the interventionalist a view 
for planning. 
Multi- phase (3 or 4 phase) CTA will be used to show the evolution of the blood flow.  This 
technique is particularly useful in demonstrating regional blood flow hang -up and implicated distal 
circulation occlusions.  The timing of mCTA imaging depends upon the individual CT scanner 
and table speed. By vendor, there is approximately 5- 8 se conds between phases.   See: 
www.aspectsinstroke.com . 
Scoring of Collateral Status 
The CTA will be assessed for collateral status using a standardized technique similar to the 
ESCAPE trial. Collaterals are measured on mul ti-phase CTA by comparing backfilling pial vessels  
beyond the blocked artery to similar vessels  in the opposite , unaff ected hemisphere (Figure A1).  
This is done for all phases of the CTA, which depending upon the machine type will vary from 5-
8 seconds apart in time.  Vascular enhancement distal to occlusion is scored in anterior and 
posterior MCA territories as visualiz ed on all CTA slices, and typically reviewed on axial thick 
maximal intensity projections (MIPs). By examining all 3 phases, the degree of filling of the pial 
vessels in time can be assessed.  Delayed filling and delayed washout ipsilateral to the occluded 
artery is expected.  The aim in the ESCAPE -NA1 trial is to exclude patients with absent or near 
absent pial collateral filling on all phases of the CTA.  Phase 1 (early) absence or minimal filling 
with later (phase 2 and 3) robust filling represents strong collaterals and an ideal treatment 
candidate.  
The following scoring system provides a guide.  Patients with a score of 0 or 1 will be excluded 
for this study. 
Category  Score  Description  
Good  5 Compared to asymptomatic contralateral hemisphere, there is no delay 
and normal or increased prominence of peripheral vessels/ normal extent 
within the occluded arteries territory within the symptomatic hemisphere.  
4 Compared to asymptomatic contralateral hemisphere there is a delay of 
one phase in filling in of peripheral vessels but prominence and extent is 
the same.   
Intermediate  3 Compared to asymptomatic contralateral hemisphere there is a delay of 
two phases in filling in of peripheral vessels but prominence and extent is 
the same or there is a one phase delay and decreased prominence (thinner 
vessels) / reduced number of vessels in some part of the territory 
occluded.   
2 Compared to asymptomatic contralateral hemisphere there is a delay of 
two phases in filling in of peripheral vessels and decreased prominence 
and extent or a one -phase delay and some regions with no vessels in 
some part of the territory occluded.   
Poor  1 Compared to asymptomatic contralateral hemisphere there are just a few 
vessels visible in any phase within the occluded vascular territory.   
0 Compared to asymptomatic contralateral hemisphere there are no vessels 
visible in any phase within the occluded vascular territory.   
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 83 of 88
*On a single phase, multiphase or dynamic CTA:  no or minimal collaterals in a region greater
than 50% of the MCA territory when compared to pial filling on the contralateral side can also
be considered as poor collaterals  (Score = 1).
Figure A1. Upper panel shows a patient with a left M1 MCA occlusion (arrow) and good collaterals 
(backfilling arteries) on multi- phase CTA. Middle Panel shows a patient with a left M1 MCA occlusion 
(arrow) and intermediate collaterals. Lower panel shows a patient with a right M1 MCA occlusion (arrow) and poor collaterals (minimal backfilling arteries) on multi -phase CTA.  
 
A teaching slide set and module will be available for use within the trial.  

NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 84 of 88
22 Appendix 3 – Randomization Detai ls. 
The initial randomization of the first 40 subject will be completed using a simple random number 
generator yielding an unblocked randomization with an equal probability for each treatment arm. 
Thereafter, randomization will be stratified by intravenous alteplase use and declared endovascular 
approach combined with a randomized minimization method from Zhao et al, called the minimal 
sufficie nt balance method23.  This approach wil l ensure that the subjects entered into the trial will 
be matched between control and active treatment arms on the key variables of age, sex, baseline 
NIHSS score, baseline ASPECTS score, occlusion location (MCA or ICA), and site. This method will ensure that during the trial and by the end of the trial, the subjects are well matched for important prognostic variables and therefore the chance that any treatment effect is confounded by 
a specific variable is severely attenuated, because the groups are balanc ed on known important 
prognostic variables . Minimization will also provide some assurance that adequate balance will be 
maintained even at the time of interim analysis.  
A randomization website, using user and site level secure access, will assign treatment  in real time. 
Five key clinical variables (age, sex, baseline NIHSS score, baseline ASPECTS score, occlusion 
location (MCA or ICA) ), and one site variable, defined by the user log in credentials, will be used 
in the minimization procedure.  Age will be c alculated against the central server date and time, 
which will be synchronized weekly to the Denver atomic clock. In this method, balance will be 
checked on the six variables using a simple t -test for continuous variables and a χ 2 test for binary
variables .  If the p -value for the test is <0.3, then imbalance is considered present and a vote is 
given to that variable to randomize to Group A or Group B to minimize imbalance.  If the 
summation of six votes favours, for example, Group A allocation, then a biased coin randomization probability of 0.65 is used and the probability of allocation to Group A becomes 0.65.  If the votes are equal, then the probability remains 0.5.  This methodology was successfully used in the ESCAPE trial
3.  A permutation test for covariate balance was undertaken at the end of the trial and 
showed no evidence of biased treatment allocation.  This same approach will be repeated in the ESCAPE -NA1 trial to demonstrate that the minimization algorithm was effective.   Treatment 
assignment will always be fully concealed since it will be assigned in real- time based upon random 
number generation. 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 85 of 88 
 23 REFERENCES  
1. Lan KKG DD. Design and analysis of group sequential tests based on type- I error 
spending rate function. Biometrika 1987;74:149 -54. 
2. O'Brien PC FT. A multiple testing procedure for clinical trials. Biometrics 
1979;35:549- 56. 
3. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid 
endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019 -30. 
4. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic s troke 
with perfusion- imaging selection. N Engl J Med 2015;372:1009 -18. 
5. Saver JL, Goyal M, Bonafe A, et al. Stent- retriever thrombectomy after intravenous t-
PA vs. t -PA alone in stroke. N Engl J Med 2015;372:2285- 95. 
6. Jovin TG, Chamorro A, Cobo E, et a l. Thrombectomy within 8 hours after symptom 
onset in ischemic stroke. N Engl J Med 2015;372:2296- 306.  
7. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial 
treatment for acute ischemic stroke. N Engl J Med 2015;372:11 -20. 
8. Cook DJT, L.; Tymianski, M. Treatment of Stroke with a PSD95 inhibitor in the 
Gyrencephalic Primate Brain Nature 2012;483:213 -7. 
9. Sun HS, Doucette TA, Liu Y, et al. Effectiveness of PSD95 inhibitors in permanent and 
transient focal ischemia in the rat. Str oke 2008;39:2544- 53. 
10. Cook DJT, L.; Tymianski, M. A translational paradigm for the preclinical evaluation of 
the stroke neuroprotectant Tat- NR2B9c in gyrencephalic nonhuman primates. Science 
Translational Medicine 2012;4:1 -8. 
11. Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA -1 in patients with 
iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, 
double -blind, placebo -controlled trial. Lancet Neurol 2012;11:942 -50. 
12. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between 
NMDA receptor subunits and the postsynaptic density protein PSD -95. Science 
1995;269:1737- 40. 
13. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA 
receptor - PSD -95 protein interactions. Science 2002;298:846 -50. 
14. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. 
CerebrovascDis 2004;17 Suppl 1:1- 6. 
15. Bratane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by 
Freezing Ischemic Penumbra Evolution Without Cerebral Blood Flow Augmentation With a Postsynaptic Density -95 Protein Inhibitor. Stroke 2011;42:3265- 70. 
16. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after 
acute ischemic stroke. NEnglJMed 2008;359:1317- 29. 
17. Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA -1 in patients with 
iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, 
double -blind, placebo -controlled trial. The Lancet Neurology 2012; 11:942- 50. 
18. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after 
intravenous t- PA versus t -PA alone for stroke. N Engl J Med 2013;368:893- 903.  
19. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular 
treatment for ischemic stroke. N Engl J Med 2013;368:914- 23. 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 86 of 88 
 20. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute 
ischemic stroke. N Engl J Med 2013;368:904- 13. 
21. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict 
clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for 
understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508 -17. 
22. Puetz V, Dzialowski I, Hill MD, Demchuk AM. The Alberta Stroke Pr ogram Early CT 
Score in clinical practice: what have we learned? International journal of stroke : official 
journal of the International Stroke Society 2009;4:354 -64. 
23. Zhao W, Hill MD, Palesch YY. Minimal Sufficient Balance – A new strategy to balance 
baseline covariates and preserve randomness of treatment allocation. Stat Meth Med Res 
2012;In press.  
24. Johnston SC, Leira EC, Hansen MD, Adams HP, Jr. Early recovery after cerebral 
ischemia risk of subsequent neurological deterioration. Ann Neurol 2003;5 4:439 -44. 
25. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for 
symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915 -24. 
26. Krol AL, Dzialowski I, Roy J, et al. Incidence of radiocontrast nephropathy in patients 
undergoing acute stroke computed tomography angiography. Stroke 2007;38:2364- 6. 
27. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta- analysis of N -acetylcysteine in 
contrast- induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC 
Med 2007;5:32.  
28. Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the 
prevention of contrast medium -induced nephropathy: a randomized controlled trial. Eur 
Heart J 2012.  
29. U.S. Department of Health and Human Services FaDA. Guidance for Sponsors, 
Clinical Investigators, and IRBs:  Data Retention When Subjects Withdraw from FDA -
Regulated Clinical Trials. In: Services USDoHaH, ed. Rockville, MD: Food and Drug Administration; 2008.  
30. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: 
implications for stroke clinical trials: a literature review and synthesis. Stroke 
2007;38:1091 -6. 
31. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a 
systematic review. Stroke; a journal of cerebral circulation 2009;40:3393 -5. 
32. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 
2006;5:603- 12. 
33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J 
1965;14:61- 5. 
34. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, 
properties, and application. Stroke; a journal of cerebral circulation 2011;42:1146 -51. 
35. Brooks R. EuroQol: The current state of play. Health Policy 1996;37:53- 72. 
36. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ -5D (EQ -5D-5L). Quality of life research : an international journal of 
quality of life aspects of treatment, care and rehabilitation 2011;20:1727- 36. 
NoNO Inc.   Protocol NA -1-007 
Date:  19 February  2019  Version:  9.0 (Amendment  #8) 
 
 
 Confidential  Page 87 of 88 
 37. Kaplan E GH, Weintraub S. The Boston Naming Test. Philadelphia, PA: Lea and 
Febiger;1983.  
38. Leibovitch FS VB, Ebert PL, Beresford KL, Black SE. A short bedside battery for 
visuoconstructive hemispatial neglect:  Sunnybrook Neglect Assessment Procedure (SNAP). 
J Clin Exp Neuropsychol 2012;34:359- 68. 
39. Cumming TB BJ, Linden T. The Montreal Cognitive Assessment:  Short Cognitive 
Evaluation in a Large Stroke Trial. Stroke 2011;42:2642 -4. 
40. Godefroy O FA, Roussel M, Au ribault C, Bugnicourt JM, Lamy C, Canaple S., 
Petitnicolas G. Is the Montreal Cognitive Assessment superior to the Mini- Mental State 
Examination to detect post- stroke cognitive impairment?  A study with neuropsychological 
evaluation. Stroke 2011;42:1712- 6. 
41. Graves RE BS, Fogarty J, Blair R. Boston Naming Test Short Forms:  A Comparison of 
Previous Forms with New Item Response Theory Based Forms. Journal of Clinical and Experimental Neuropsychology 2004;26:891- 902.  
42. Hong KS, Saver JL. Years of disability -adjusted life gained as a result of thrombolytic 
therapy for acute ischemic stroke. Stroke; a journal of cerebral circulation 2010;41:471 -7. 
43. group ISTc, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous 
thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic 
stroke (the third international stroke trial [IST -3]): a randomised controlled trial. Lancet 
2012;379:2352- 63. 
 
  
NoNO Inc.  Protocol NA -1-007 
Date:  19 February  2019 Version:  9.0 (Amendment  #8) 
Confidential Page 88 of 88
24 Inve
stigator’s Agreement 
I have 
read the attached protocol: A Multicentre, Randomized, Double -blinded, Placebo -
controlled, Parallel Group, Single -dose Design to Determine the Efficacy and Safety of 
Intravenous NA- 1 in Subjects with Acute Ischemic Stroke Undergoing Endovascular 
Thrombectomy (ESCAPE -NA1 Trial), Version 9.0 dated 19 February  2019 and  agree to abide 
by all provisions set forth therein. 
I ag
ree to comply with the current International Conference on Harmonisation Guidelines for 
Good Clinical Practice and the laws, rules, regulations and guidelines of the community, country, 
state or locality relating to the conduct of the clinical study.  
I al
so agree that persons debarred from conducting or working on clinical studies by any court or 
regulatory agency will not be allowed to conduct or work on studies for the sponsor. 
Name Site Principal Investigator  Signature  
Name of Clinical Site  Date  